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SUMMARY
Primary liver cancer, of which hepatocellular carcinomas (HCCs) accounts for 90%, is the 
fifth most common and third deadliest cancer worldwide. As HCCs are strongly heterogenic 
and with symptoms occurring late, the development of efficient treatment strategies is until 
now challenging. Transforming growth factor beta (TGF-) is a multifactorial cytokine and a 
driver of chronic liver disease progression, which eventually ends in HCC. TGF-, which acts 
as a tumor suppressor during cancer development, may switch to tumor-supporting 
characteristics during cancer progression. The ambiguous nature of TGF-, together with the 
strong heterogeneity of HCC, leads to a highly complex situation in regard to TGF- signaling 
during hepatocarcinogenesis. As TGF- signaling is frequently altered in HCC, it is an 
interesting target to develop new therapeutic strategies. However, this requires deep 
knowledge about the time point and underlying mechanisms of the switch in TGF- signaling.  
This question was addressed by a systematic in-depth analysis of cytostatic effects of TGF-
and mechanisms of resistance in ten commonly used liver cancer cell lines. TGF- induced 
cell death or growth arrest in one group of cell lines (PLC/PRF/5, Hep3B, HuH7 and HepG2) 
in a Smad3 dependent manner. These cells commonly expressed relatively low basal levels 
of TGF-1 and its inhibitor Smad7, but elevated levels of TRII (TGF- receptor II). 
Furthermore, they exhibited a high inducibility of Smad3 and TRI expression, Smad3 
transcriptional activity and target gene expression, as exemplified for Bim, PAI-1 and Smad7. 
Interestingly, all cell lines have previously been described to express an early TGF--
response gene signature, which was also identified in HCC patients and correlates with a 
better prognosis. In contrast, the second group (HLE, HLF, FLC-4 and to some extent HuH6 
cells) was resistant against cytostatic effects of TGF- and further characterized by high 
Smad7 and TGF-1, low TRII expression and low TGF- induced Smad3 transcriptional 
activity. In addition, all but HuH6 cells had a highly motile phenotype. HCC-M and HCC-T 
cells shared characteristics of both groups, showing, e.g., resistance against TGF- induced 
cytostasis but low TGF-1, Smad7 and TRII levels. Finally, analysis of patient samples 
showed an overexpression of Smad7 in 59 % of HCCs with a significant correlation to tumor 
size in a HBV related subgroup from China.       
In conclusion, HCC cell lines can be allocated into two main groups regarding the cytostatic 
TGF- response, which is accompanied by distinct differences in basal and TGF- induced 
expression patterns of TGF- signaling components and target genes. Smad7 upregulation 
seems to be an important mechanism in transformed hepatocytes to establish insensitivity 
against TGF- induced cytostasis, and once this is accomplished, a more malignant 
phenotype may develop. 
ZUSAMMENFASSUNG  VII 
ZUSAMMENFASSUNG
Primärer Leberkrebs, wovon 90% hepatozelluläre Karzinome (HCCs) sind, ist weltweit der 
fünfthäufigste und dritttödlichste Tumor. Eine hohe Heterogenität und spät auftauchende 
Symptome erschweren die Entwicklung effizienter Therapien gegen HCCs. Transforming 
growth factor beta (TGF-) ist ein multifaktorielles Zytokin und ein wichtiger Regulator 
chronischer Lebererkrankungen,die in HCC resultierenkönnen.TGF-,ein Tumorsuppressor 
in der Krebsentstehung, kann tumorfördernde Eigenschaften während der Krebsprogression 
annehmen. Diese duale Rolle und die hohe Heterogenität des HCCs erzeugen eine hohe 
Komplexität bezüglich des TGF--Signalweges während der Hepatokarzinogenese. Da die 
TGF--Kaskade in HCCs häufig modifiziert ist, bietet sie einen guten Ansatzpunkt für 
dringend benötigte neue Therapiestrategien. Dies setzt aber ein detailliertes zeitliches und 
mechanistisches Verständnis des Funktionalitätswechsels von TGF- voraus.  
Vor diesem Hintergrund wurde eine systematische Analyse der zytostatischen TGF-- 
Wirkung sowie möglicher Resistenzmechanismen in zehn häufig verwendeten Leberkrebs-
zelllinien  durchgeführt. TGF- induzierte über Smad3 Zelltod oder Proliferationsinhibition in 
einer Gruppe von Zelllinien mit niedriger Expression von TGF-1 und dessen Inhibitor 
Smad7, aber erhöhten TGF- Rezeptor II (TRII)-mRNA-Mengen (PLC/PRF/5, Hep3B, 
HuH7, HepG2). TGF--Behandlung führte zu einer starken Induktion der Smad3 und TRI-
Expression, der Smad3-Transkriptionsaktivität sowie der Expression der Zielgene Bim, PAI-1 
und Smad7. Diese Zelllinien wurden bereits zuvor einer Gruppe zugeordnet, die korrelierend 
mit einer besseren Prognose für Patienten sogenannte frühe TGF--Zielgene exprimiert. Die 
zweite Gruppe (HLE-, HLF-, FLC-4- und zum Teil HuH6-Zellen) war resistent gegen TGF-
induzierte Zytostase und zeigte hohe Smad7- und TGF-1-, aber niedrige TRII-Expression 
und eine abgeschwächte TGF--induzierte Smad3-Transkriptionsaktivität. Zudem besaßen 
außer HuH6 alle Zelllinien dieser Gruppe eine hohe Migrationsfähigkeit.HCC-M- und HCC-T-
Zellen zeigten Charakteristika beider Gruppen: Trotz Resistenz gegen zytostatische TGF--
Effekte waren die TGF-1-, Smad7-, aber auch TRII-mRNA-Niveaus niedrig. Eine 
abschließende Analyse von Patientenproben zeigte in 59% aller HCCs eine Smad7-
Überexpression, die in HBV-assoziierten Proben aus China mit der Tumorgröße korrelierte. 
Zusammenfassend zeigt die vorliegende Arbeit, dass HCC-Zelllinien bezüglich der zyto-
statischen TGF--Antwort zwei Hauptgruppen zugeordnet werden können, die klare 
Unterschiede in basalen und TGF--induzierten Expressionsmustern von TGF--
Signalkomponenten und Zielgenen aufweisen. Die Daten weisen darauf hin, dass Smad7-
Überexpression ein wichtiger Mechanismus zur Entwicklung einer Resistenz gegen 
zytostatische TGF--Effekte in transformierten Hepatozyten zu sein scheint. Eine so 
etablierte Resistenz könnte zur Entwicklung eines bösartigeren Phänotyps führen.
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1 INTRODUCTION
1.1 TGF- and signaling
1.1.1 TGF- and its receptors
Transforming growth factor beta (TGF
which belongs to the eponym
members belonging to two different
belong to the TGF- subfamily
consists of BMPs, growth and differentiation factors (GDF
hormone (AMH) [1, 2]. Members of the TGF
processes, such as growth arrest, apoptosis, differ
and thereby carry out important functions during
the control of the immune system and angiogenesis
progression of diverse diseases.
 Figure 1.1 Production and secretion o
TGF-1 is synthesized as a 391 amino acid pre
a pro-region and an N-terminal 112 amino acid
[4, 5] ( Figure 1.1). After cleavage of the signal sequence, a homodimeric pro
formed, with three disulfide bridges connecting bot
cut off, it remains tightly associated to the matur
associated protein (LAP). Additionally, each LAP protein is
TGF- binding protein (LTBP) 
extracellular matrix (ECM) [9
biological functions. Various proteases 
 components 
-) is a multifunctional and pro-fibrogenic 
ous TGF- cytokine family. In humans, it comprises 
 subgroups: TGF- isoforms 1-3, the 
, whereas the bone morphogenetic protein (BMP) subfamily 
s) as well as anti
- family are involved in a wide range of cellular 
entiation, matrix remodeling 
, e.g., embryogenesis, tissue homeostasis
, as well as during development and 
f latent TGF- (based on [3]). See text for details.
-pro-peptide consisting of a signal sequence, 
sequence encoding the TGF
h chains. Once the dimeric pro
e TGF- dimer, giving it the name latency 
covalently bound to the latent 
[6-8], which is involved in the association of 
]. In this complex, TGF- is inactive and not able to e
(e.g., plasmin [10]), but also non-proteolytical proteins 
1 
cytokine, 
at least 33 
activins and Nodal 
-Müllerian 
and migration 
, 
- monomer 
-peptide is 
-region is 
TGF--LAP with 
xert its 
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(e.g., thrombospondin 1 [11] and integrins [12, 13]) and environmental factors such as a mild 
acidic pH [14] are able to activate TGF-.  
Activated TGF- signals through cell surface transmembrane serine/threonine kinase 
receptors. It induces the formation of a heterotetrameric type I (TGF- receptor 1, TRI) and 
type II (TGF- receptor 2, TRII) receptor complex (Figure 1.2): Mature TGF- dimers bind to 
constitutively active TRII, which results in a recruitment of two TRI molecules between two 
type II receptors [15-17]. TRI and TRII are structurally similar proteins containing an
extracellular ligand binding domain, a transmembrane region and a C-terminal intracellular 
domain with a serine/threonine kinase. TRII phosphorylates TRI at a glycine-serine-rich 
sequence, just N-terminal of the kinase domain, leading to activation and subsequent 
autophosphorylation of TRI. Activated type I receptors are then able to transmit the signal to 
soluble TGF- signaling components within the cells, to so called receptor (R)-Smads (see 
chapter 1.1.2, reviewed in [18,19]).  
Despite a high number of different members in the TGF- superfamily, their signal is 
mediated by only five type II and seven type I receptors. Each cytokine binds to a specific 
combination of type I and II receptors, allowing for a diverse and specific signal conversion 
(outlined in [18]). The main signaling mediators for TGF- were identified to be TRII, TRI 
(activin receptor-like kinase 5, ALK5), R-Smads 2 and 3 [18, 20]. However, binding of TGF-
by other type I receptors was found in endothelial (ALK1) [21, 22] and epithelial (ALK2 or 
ALK3) cells [23], both in an ALK5 dependent manner and leading to the activation of 
R-Smads 1 and 5 instead of Smad2 and 3 (see chapter 1.1.2) [23, 24].  
1.1.2 Canonical TGF-β signaling 
The intracellular canonical signaling of the TGF- superfamily is mediated and controlled by 
the so-called "mothers against decapentaplegic" or Smad proteins. The Smad family consists 
of eight members of whom five are receptor (R)-Smads (Smad1, 2, 3, 5 and 8), one is a 
universal signaling partner (Smad4) and two, Smad6 and Smad7, are inhibitors of some 
signaling branches (reviewed in [25]). R-Smads and common (co)-Smad4 are structurally 
subdivided in a conserved N-terminal Mad-homolgy (MH) 1 and a C-terminal MH2 domain 
with a flexible linker region in between (Figure 1.3) [25-27].  
Upon ligand binding, heterotetrameric receptor complexes transfer the cytokine signal into 
the cell through phosphorylation of a specific R-Smad subset (chapter 1.1.1). TGF- mainly 
activates Smad2 and Smad3 through phosphorylation of two serine residues within a highly 
conserved C-terminal serine-X-serine (SXS) motif [28]. All the different activated R-Smads 
Introduction
associate to the same protein, common mediator (co)
Smad4 protein to form a heterotrimeric transcriptio
translocate into the nucleus to mod
 Figure 1.2 Canonical and non-
mentioned in this thesis
chapter 1.1.   
Smad3/Smad4 recognize a specific palindromic DNA se
Smad binding element (SBE). Here, a conserved 
domain binds a 5’-GTCT-3 or the reverse 5’
Smad2 is unable to directly interact with 
next to the crucial -hairpin 
activity by additional associations with DNA bindi
signal transducer 1, FoxH1) leading t
The Smad binding element (SBE)
recognition side and the binding of Smad3 happens w
SBE is usually in close proximity to recognition sites of Smad
able to increase the Smad-DNA
various transcription factors
nuclear receptor family proteins)
Smad2/3 to regulate p21Cip1 expression
-Smad4. Two R
n factor [29]. These 
ify expression of a broad spectrum of gene
canonical TGF- signaling (modified from [30] and other publications 
). CoA = Co-activator, TF = transcription factor. For further d
quence (5’-GTCTAGAC
-hairpin structure within the 
-CAGA-3 sequence. In contrast to Smad3, 
DNA, caused by an interfering amino acid sequence 
[27, 31, 32]. Smad2/Smad4 therefore exert its transcriptional 
ng proteins, e.g., FAST-1
o activation of an activin response element (ARE) 
 by itself is a very short nucleotide sequence for a protein 
ith low affinity [32
-interacting factors
 binding efficiency. Therefore, R-Smad proteins interact with 
of different classes (e.g., zinc finger proteins, forkhead a
: FoxO (Forkhead box O), for example, 
 [34] or Sp-1 (stimulating protein 1) associates with 
3 
-Smads bind one 
complexes then 
s (Figure 1.2). 
etails see 
-3’) called 
Smad3 MH1 
 (Forkhead activin 
[33]. 
]. In promoters, a 
, which are 
nd 
cooperates with 
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Smad2 and/or Smad3 to activate various TGF- target genes (e.g., p15Ink4B, [35],p21Cip1 [36], 
Smad7 [37], PAI-1 (plasminogen activator inhibitor-1) [21, 22] or Collagen Col1A [38]) and 
many others (reviewed in [18, 39]). However, R-Smads may also inhibit gene expression. 
Smad3, for instance, cooperates with the transcription factor E2F4/5 and the co-repressor 
p107 in order to exert repressive effects of TGF- on the proto-oncogene c-Myc [40]. Here, 
Smad3 recognizes, as opposed to the classical mechanism, a repressive binding element 
(5’-TTGGCGGGAA-3’) [41]. 
Additionally, Smad proteins are known to interact with a broad range of cofactors (reviewed 
in [18]), which modulate the intensity of the target gene expression. While co-activators such 
as CBP/p300 (CREB binding protein) increase the activity of the Smad transcription factor 
complex [42, 43], it is reduced by co-repressors such as c-Myc [44] and YB-1 (Y box binding 
protein 1, a mediator of inflammatory interferon-gamma (INF-) signaling) [38]. 
Figure 1.3 Structure of receptor, common mediator and inhibitory Smad proteins (based on reviews 
[25,45] and publications in the text). The figure shows a simplified Smad structure, mainly with 
motifs discussed in this thesis. See chapter 1.1.2, 1.1.3 and 1.1.4.2 for further details.  
A third subgroup of the Smad family members is formed by Smad6 and Smad7; two potent 
inhibitors of TGF- superfamily signaling [46-48]. Inhibitory (I)-Smads share a conserved 
MH2 domain with the R-Smads (Figure 1.3). However, they lack the C-terminal serine-X-
serine motif, which is fundamental for R-Smad signaling. Additionally, N-termini of I-Smads 
are shorter and less conserved than the ones of other Smads [47, 49, 50]. I-Smad 
expression is upregulated in a negative feedback mechanism by different members of the 
TGF- cytokine superfamily [48, 51-53]. While Smad7 is a more general inhibitor, interfering 
with TGF- and BMP subfamily signaling, Smad6 mainly antagonizes the latter [46-49, 54, 
55]. Smad7 will be extensively discussed in chapter 1.1.4. Next to I-Smads, other proteins 
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are also able to terminate TGF- signaling, e.g., TGF- target genes Ski and SnoN. They 
inhibit the association of the Smad-DNA binding complex with the co-activator p300 [56, 57]. 
Many other mechanisms exist to regulate duration and intensity of TGF- signaling. For 
example, phosphatase PPM1A dephosphorylates Smad2/3 and thereby shortens the nuclear 
stopover of Smad complexes [58].  
In conclusion, canonical TGF- superfamily signaling represents a relatively straightforward 
signaling cascade whose different effects are mediated by seven type I and five type II 
receptors and are specifically converted by five receptor Smad molecules. TGF- signaling 
itself is mainly exploited by TRI, TRII and Smad2/3. However, a broad variety of different 
collaborating factors ensures a cell type and context specific target gene expression and 
thereby creates a more complex picture. TGF-’s ability to additionally exert Smad 
independent functions and cross-talk with a number of other signaling pathways further 
increases this intricacy (next chapter).  
1.1.3 Non canonical TGF- signaling and cross-talk with other pathways 
TGF- exerts its functions not only via the classical canonical signaling pathway, but also 
modulates a broad spectrum of different pathways in a Smad independent and often cell type 
and context dependent manner (Figure 1.2, left). For example, TGF- activates the mitogen 
activated protein kinase (MAPK) pathway, which transmits either survival signals via Ras and 
ERK (extracellular signal-regulated kinase) or, activating p38 or JNK (c-Jun N-terminal 
kinase), stress signals. TGF- may induce the interaction of TRI with adaptor protein ShcA 
(src homology domain containing transforming protein) leading to activation of Ras and 
ultimately MAP kinase ERK [59]. ERK activation by TGF- was found in epithelial cells and 
fibroblasts [59-61], for example, and was shown to participate in induction of EMT (epithelial 
to mesenchymal transition) [62, 63]. Similarly, TGF- may induce stress mediated MAPK 
signaling via activation of JNK or p38 [64-67]. One possible mechanism suggests the 
involvement of TRAF6/TAK-1 (TNF receptor associated factor 6/TGF--associated kinase-1) 
and links TGF- induced apoptosis and EMT to p38 and JNK mediated signaling [67, 68]. 
Another non-canonical pathway utilized by TGF- is phosphatidylinositide3-kinases 
(PI3K)/Akt signaling, which can be involved in TGF- mediated survival signaling or EMT in 
epithelial cells [69-71] and induction of proliferation in mesenchymal cells [72]. Intriguingly, 
TGF- may also block Akt activity, which, for example, may happen during TGF- induced 
apoptosis [73, 74]. Finally, RhoA (Ras homolog family member A) and Cdc42 (Cell division 
cycle 42) of the Rho family of GTPases, offer another possibility for TGF- to affect R-Smad 
independent signaling pathways. They are involved in the regulation of intracellular actin 
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dynamics and stress fiber formation, and their activation by TGF- is linked to EMT (RhoA) 
and alterations of the actin cytoskeleton (Cdc42) [75-77]. Smad7 can be an important 
scaffold protein which mediates some non-canonical TGF- signaling by recruiting non-Smad 
proteins to the TGF- receptor complex (chapter 1.1.4.3).
While TGF- regulates several independent signaling cascades, canonical TGF- signaling, 
in turn, can also be modified by cross-talking signaling pathways. A common motif is the 
phosphorylation of linker regions of the R-Smads (Figure 1.3). Unlike the C- and N-terminal 
domains, the connecting region is less conserved between the different Smad proteins, 
offering an additional and more specific regulation level. Linker regions are modified at ERK 
consensus sites and serine/proline motifs, which are recognized by proline-directed kinases 
[78]. Cycline dependent kinases (CDK) 2 or 4 mediate linker phosphorylation of Smad2 and 
3 and thereby decrease TGF- induced p15 expression and growth arrest [79]. Cam kinase II 
(Ca2+-calmodulin-dependent protein kinase II) preferentially phosphorylates linker regions of 
Smad2 and inhibits its nuclear translocation [80]. Finally, IL-1 (interleukin 1-beta) induces 
JNK mediated linker phosphorylation of Smad3. Interestingly, TGF- itself is able to use this 
signaling branch and an increasing ratio of linker/C-terminal phosphorylation is observed 
during liver disease progression [81, 82]. Additionally, other mechanisms exist to regulate 
R-Smads, e.g., Akt, which hinders activated Smad3 to enter the nucleus (see chapter 1.4.2).  
1.1.4 Smad7 – inhibitor of canonical TGF- signaling and cross-talk mediator 
TGF- is a key regulator of various cellular processes and is involved in many (patho-) 
physiological processes. Logically, it is tightly regulated by different mechanisms, often with 
Smad7 as a key player. Coherently, Smad7 activity, as a potent inhibitor of canonical TGF-
signaling, is also carefully controlled. Additionally, Smad7 is an important cross-talk mediator.  
1.1.4.1 Inhibition of canonical TGF- signaling by Smad7 
Smad7, as an effective inhibitor of canonical TGF- signaling, exerts its inhibitory functions 
via various mechanisms (outlined in [2]): 
a) Binding of TGF- receptor 1 (TRI)  
Due to the conserved MH2 domain (chapter 1.1.2), Smad7 is able to compete with 
R-Smads for the binding sites of TRI. It forms a stable complex with the type I 
receptor leading to decreased activation of R-Smads and canonical TGF- signaling 
[46, 48, 83, 84].  
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b) Smad7 as anadapter protein to promote TGF- receptor 1 degradation 
E3 ubiquitin ligases Smurf1/2 (Smad specific E3 ubiquitin protein ligase), Tiul1 and 
NEDD4-2 recruit nuclear Smad7 to the active TGF- receptor complex to initialize 
lysosomal or proteasomal degradation of TRI and, except for Tiul1, Smad7 itself [85-
89].  
c) Induction of TGF- receptor 1 dephosphorylation 
Next to induction of type I receptor degradation, Smad7 is also able to regulate it 
reversibly by mediating dephosphorylation of the activated TRI and ALK1 by 
GADD34-PP1c (growth-arrest and DNA-damage-inducing protein 34-protein 
phosphatase 1c) and PP1, respectively [90, 91].  
d) Interactions with proteins assisting Smad7 with regulation of TRI 
Proteins, such as STRAP (serine/threonine kinase receptor-associated protein) [92], 
SIK (salt-inducible kinase) [93] and many more (reviewed in [2]) were shown to 
interact with Smad7 in order to modify TRI activity.  
e) Blocking DNA binding sites 
Smad7 is present in the nucleus and cytoplasm. It can interfere with TGF- signaling 
by competing with Smad transcription factor complexes for the corresponding DNA 
binding sites [94]. Additionally, Smad7 interacts with acetyltransferase p300 [95] as 
well as histone deacetylase 1 (HDAC1) [96] and is thereby possibly able to regulate 
TGF- target gene transcription by epigenetic modifications.  
f) Binding of Smad4 and inducing its degradation 
Smurfs directly interact with R- and I-Smads via specific motifs within the Smad linker 
region. Smad4 does not possess this motif (Figure 1.3). However, Smad7 is able to 
interact with Smad4 and thereby facilitate Smurf1 mediated degradation of Smad4. 
Similar collaborative effects were observed for Smurf2, Tiul1 and NEDD4-2 [97].   
1.1.4.2 Regulation of Smad7  
Smad7 is an important regulator of TGF- signaling. Because of that, it is tightly controlled by 
different factors and mechanisms (summarized in [2]): 
a) Negative feedback loop 
Smad7 is directly induced by canonical TGF- signaling because of a Smad binding 
element within the Smad7 promoter [37, 98-100]. Optimal induction of the inhibitor’s 
expression is reached when the R-Smad/Smad4 complex cooperates with other 
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transcription factors, e.g., AP-1 (activator protein-1) or Sp-1 [37, 98, 101] and co-
activators such as CBP/p300 [43, 100]. Many of those factors are regulated by other 
pathways underlining the role of Smad7 as cross-talk mediator (see chapter 1.1.4.3).  
b) Regulation of Smad7 stability by induction of proteasomal degradation 
Smad7 is able to recruit Smurf1/2 for degradation of TRI and reduction of 
TGF- signaling. This leads to the decomposition of the inhibitor itself (see above). 
Additionally, Jab1 and Arkadia mediate nuclear export, ubiquitination and degradation 
of Smad7, resulting in enhanced TGF- signaling [102, 103].  
c) Regulation of Smad7 stability by acetylation 
p300 acetylates Smad7 at two lysine residues (Figure 1.3) and thereby inhibits 
Smurf-mediated degradation of the inhibitor (see above) [95]. HDAC1 [96], on the 
other hand, can reverse this effect by deacetylation of Smad7.     
d) Induction of Smad7 expression by TGF- antagonizing pathways 
Because Smad7 is a potent inhibitor of canonical TGF- signaling, its expression is 
induced by many antagonizing pathways (discussed in chapter 1.1.4.3).    
1.1.4.3 Smad7 and its importance as cross-talk mediator 
On the one hand, TGF- signaling is involved in the regulation of many different processes 
and therefore needs delicate fine tuning, which includes interaction with other signaling 
pathways. On the other hand, TGF- is involved in the regulation of other signaling 
cascades. Smad7 plays an important role as mediator of those interacting pathways (cross-
talk).  
TGF- is a pro-fibrogenic and anti-inflammatory cytokine and therefore exerts inhibitory 
effects on several opposing proteins (summarized in [104]), e.g., tumor necrosis factor alpha 
(TNF-) or IL-1 [105]. Vice versa, it is not surprising that pro-inflammatory cytokines 
(illustrated in Figure 1.4, left), such as IFN- [100, 106, 107], IL-1 and TNF- directly induce 
Smad7 expression to suppress TGF- effects [108]. Next to inflammatory pathways, Smad7 
is induced by other factors, e.g., epidermal growth factor (EGF) [51] and HER2 (human EGF 
receptor 2) [109] or by UV irradiation [110]. 
Smad7 was shown to be involved in the regulation of several proteins belonging to other 
pathways (Figure 1.4, right). TGF- dependent activation of the TRI-TRII complex may as 
well result in a recruitment and activation of TRAF6, which in turn leads to activation of 
TAK-1, MAPK kinases (MKKs) and ultimately MAP-kinases JNK or p38 [67, 111]. Smad7 is 
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Smad independent signaling pathways by TGF-. In both situations, ambiguous effects can 
be sometimes observed and the final outcome is likely cell and context dependent. 
1.2 Effects of TGF- on cytostasis and epithelial-to-mesenchymal 
transition (EMT) 
TGF- is a well recognized mediator of programmed cell death (apoptosis) in various cell 
types, including B- and T-cells, lymphocytes, endothelial and epithelial cells (reviewed in 
[123]), and hepatocytes [71, 124]. Since then, different possibly involved pathways (Smad 
dependent and independent) were identified, but the situational and mechanistic 
understanding still needs improvement in some areas.  
For some cell systems, a non-canonical, but Smad7 dependent mechanism was identified for 
TGF- induced apoptosis (chapter 1.1.4.3). In non-transformed murine hepatocytes (AML-12 
cell line), TGF- exerts its proapoptotic functionality via recruitment of DAXX (Death-
associated protein 6) to TRII and subsequent activation of JNK [125]. In primary human 
hepatocytes and some, but not all, liver (cancer) cell lines, TGF- enhances TRAIL 
(TNF-related apoptosis inducing ligand) expression in a Smad4 and AP-1 dependent 
manner. Herzer et al demonstrated that TGF- induced cell death is at least partly TRAIL 
dependent in those cell lines which are responsive to the death ligand [126, 127]. 
Furthermore, Smad dependent initiation of apoptosis in primary murine hepatocytes is 
mediated by Smad3 and not Smad2 in dependency of p38 [128, 129]. In fetal rat 
hepatocytes, ROS production by NADPH oxidase 4 (NOX4) was identified as a key mediator 
of TGF- induced apoptosis, involving Bcl-XL reduction, increased caspase 3 activity and the 
release of mitochondrial cytochrome C into the cytosol [130, 131]. 
In the past, induction of apoptosis has been considered as the main task of TGF-. However, 
this is not true for all circumstances and the response of hepatocytes is more likely context 
dependent: In healthy liver TGF- and activin seem to fulfill anti-proliferative tasks and 
thereby keep hepatocytes in a quiescent state [132]. In general, TGF- is a well known 
inhibitor of cell division in endothelial, hematopoietic and, especially, epithelial cells 
(reviewed in [133]). The mechanism is cell type specific but it often leads to inactivation of 
cyclin dependent kinases (CDKs), key components of the cell cycle, or to downregulation of 
pro-proliferative c-Myc. CDK activity is tightly controlled by different mechanisms; by CDK 
inhibitors of the INK4 or Cip/Kip protein family, among others. TGF- exerts its anti-
proliferative tasks by upregulation of some of those inhibitors, e.g., p15INK4b [35, 134] and 
p21CIP1 [36, 135], or by interference with CDK4 expression [136]. Moreover, TGF- inhibits 
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c-Myc expression (see chapter 1.1.2) and thereby overrides the repression of p15 and p21 
transcription [137, 138]. 
Another important effect of TGF- on hepatocytes is the induction of epithelial to 
mesenchymal transition (EMT). EMT is a process during which an epithelial cell detaches 
from the epithelial cell assembly and adopts a mesenchymal like and more motile phenotype. 
TGF- induced EMT comes along with several changes in TGF- target gene expressions 
[139]: While epithelial markers such as E-cadherin or zonula occludens 1 (ZO-1) are 
repressed, an increase in typical mesenchymal markers, such as vimentin, can be observed. 
Additionally, TGF- induces expression of profibrogenic genes, e.g., TIMP-1 (Tissue inhibitor 
of metalloproteinase 1), collagens and PAI-1, which suggests that hepatocytes contribute to 
changes in extracellular matrix composition during fibrogenesis [139, 140]. 
1.3 Hepatocellular carcinoma 
In 2008, an estimated 12.7million new cancer cases and 7.6million cancer related deaths 
were counted worldwide. With about 750000 cases and 694000 deceased, primary liver 
cancer is the sixth most common and third deadliest cancer and has with 93% one of the 
highest mortality rates of all. For men, it is even among the top 5 of the most common and  
  the second most lethal cancer worldwide with 2.4times more incidences than women (Figure 
1.5). Almost 84 % of all incidences occur in developing countries, while, except for Southern 
Europe, liver cancer is not as common in well developed areas. In Europe, for example, it 
was ranked number 13 of the most frequent tumor types but was responsible for the 7th 
highest cancer related mortality rate (Globocan2008 database of the International Agency for 
Research on Cancer, IARC [141]). Nevertheless, liver cancer caused increasing interest 
towards the end of the last millennium because, between 1970 and 1990, age standardized 
incidence rates were constantly rising in many European countries (CI5plus database of the 
IARC [142]). Hepatocellular carcinoma (HCC) derives from transformed hepatocytes and 
represents, with about 85-90%, the majority of all primary liver cancers. Other tumors 
belonging to this group are, for example, hepatoblastomas and intrahepatic bile duct 
carcinoma (intrahepatic cholangiocarcinoma, iCCC) [143]. 
The liver is a highly regenerative organ, which is therefore able to fulfill its most important 
tasks even under difficult circumstances. Due to this, liver cancer can often silently develop 
over a long period of time, reaching big tumor sizes without symptoms. This results in a late 
diagnosis and is the main reason for the high lethality of HCC [144]. Even in well developed 
countries, in 2003 only a minority of 30-40% of HCC patients was diagnosed at an early 
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stage, and thus suitable for the most promising treatment options such as tumor resection, 
radiofrequency ablation and liver transplantation [145]. In 2005, early diagnosed HCCs 
treated with those therapies reached five year survival rates above 50 % in some studies, 
while treatment following the first occurrence of symptoms resulted in very poor prognosis 
with survival rates below 10 % (reviewed in [146]). Sorafenib (a comparably new treatment 
option for HCC) was hailed as a success when survival rates increased by 3 months. This 
provides a good example of how limited treatment options are to date [147, 148]. Therefore, 
new therapeutic strategies and tools for diagnosis are urgently needed. 
Figure 1.5 Estimates of new cancer incidences and mortality worldwide in 2008 (according to Globocan 
2008 v2.0, Cancer Incidence and Mortality Worldwide [141]). Numbers of new cases and deaths of 
the 15 most common cancers are shown for males (blue) and females (pink).
Development of HCC is thought to be a complex, multi-factorial and multistep process, which 
is the underlying reason for its complex molecular pathogenesis. A broad variety of well 
defined factors, dependent on gender, geographic area and race could be associated to 
occurrence of HCC. Up to 80% of all HCCs arise in cirrhotic liver caused by different liver 
diseases [145]. Estimated age-standardized incidence rates per 100 000 inhabitants varied 
from 1.6 for females from Northern Europe or South Central Asia to 35.5 for males in Eastern 
Asia (Globocan 2008 database [141]). In China, Hepatitis B virus (HBV) is the main cause of 
HCC, while hepatitis C virus (HCV) and alcohol abuse related HCC are the dominant 
etiologies in Western countries, including Germany. Aflatoxin B1, a mycotoxin produced by 
mold fungus, causes liver inflammation, which if chronic may lead to fibrosis, advance to 
cirrhosis and ultimately end in HCC. Aflatoxin B was identified as a common etiology of HCC 
in Africa where fungus contaminated food is consumed regularly. Other risk factors are, e.g., 
diabetes, smoking and obesity (reviewed in [144, 145]). The different etiologies suggest that 
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the incident rate of HCC can be significantly reduced by different approaches, such as 
vaccination against HBV or avoidance of contaminated food. Until then, diagnosis and 
therapy strategies urgently need to be improved. 
1.4 TGF- and cancer 
TGF- is evolutionarily considered a rather young cytokine, only occurring during the 
appearance of vertebrates in order to support the development of increasingly complex 
organisms. It is involved in the regulation of complex epithelial and neural networks, the 
immune system, wound healing and many more processes [149]. Overtaking such important 
functions, it is not astonishing that malfunctioning TGF- signaling results in a broad variety 
of different diseases, such as cancer, among others.  
1.4.1 The TGF- paradox 
TGF-, with its pro-apoptotic and anti-proliferative nature, was first identified as a tumor 
suppressor, which was confirmed in vivo in a heterozygous TGF- knockdown mouse model: 
In these animals, chemically induced tumorigenesis in liver and lung is enhanced suggesting 
an inhibitory function of TGF- during tumor initiation [150]. The majority of all cancers are of 
epithelial origin (carcinomas) [151, 152], and the growth limiting and apoptosis inducing 
effect of TGF- on epithelial cells is well documented. Paradoxically, TGF- is highly present 
in several cancers, e.g., T cell leukemia, colorectal cancer and renal and breast carcinoma 
[153-157]. Elevated amounts of the cytokine were also detected in human HCC and 
malignant hepatocytes were identified as one source for the overexpression [158, 159]. 
Increased TGF- levels can often be correlated to increased tumor aggressiveness and 
poorer prognosis [156, 157], indicating that TGF- may as well act as an oncogene. Indeed, 
TGF- was not only found to exert anti-tumorigenic functions, but, in certain contexts, also to 
promote tumor growth and progression (see chapter 1.4.2). This ambiguous behavior of 
TGF- and its signaling components is described as “the TGF- paradox”. The dual role of 
TGF- signaling during carcinogenesis was nicely demonstrated in a chemically induced 
murine skin cancer multistage-model. TGF- overexpression decreases the total number of 
benign skin papillomas. However, this relatively low tumor number shows an explicit 
enhancement of malignant transformation compared to wild type animals [160]. TGF-
signaling is tightly controlled by several factors. Smad7 is a potent inhibitor of the canonical 
TGF- signaling cascade and is therefore defined as a potential tumor promoter in healthy 
tissue. Similar to the ambiguous effects of TGF- in cancerogenesis, its inhibitors, e.g., 
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Smad7 (discussed in chapter 1.4.3), Ski and SnoN [161] may also overtake tumor promoting 
and suppressing tasks. Hence, the functional outcome is probably dependent on the context 
and the stage of disease.  
Figure 1.6 The ambiguous functions of TGF- signalling during tumorigenesis (taken from [162]) 
Many findings indicate that neoplastic cells may convert TGF- from a tumor suppressor to a 
tumor promoter (reviewed in [149, 163, 164]). However, this switch from anti- to 
protumorigenic behavior is not a mandatory step. During cancerogenesis, two different 
scenarios are imaginable, which were discussed in detail by Joan Massague [149]:     
a) TGF- acts as a tumor suppressor as it is a strict regulator of, e.g., tissue 
homeostasis, as well as apoptosis, proliferation, differentiation, survival and 
adhesion. In a functional TGF- signaling cascade, this cytokine is therefore able to 
inhibit development of tumors or their progression to more malignant stages. Cancer 
cells can circumvent those effects by virtually inhibiting the whole TGF- signaling 
cascade. This is accomplished by inactivation of main signaling components such as 
TGF- receptors.  
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b) In a second scenario, not core but downstream components are inactivated. 
Dependent on the affected protein, this could lead to a specific aberration of the 
cytostatic TGF- branch, while other TGF- signaling tasks are still functional. In 
doing so, cancer cells can still benefit from the pro-oncogenic nature of TGF-. 
Thus, inactivation of TGF- signaling at the very start may inhibit tumor suppressive effects. 
However, inhibitory aberrations in specific downstream components may not only block 
growth inhibitory effects of TGF- but also allow tumor cells the use of other TGF- functions 
to promote tumor growth or malignant transformation. The dual role of TGF- underlines the 
importance to fully understand TGF- signaling in a time and context deciphered manner in 
order to develop adjusted therapy strategies. Further, the double edged behavior of TGF- is 
the basis for its possible involvement in almost all fundamental steps during tumorigenesis, 
the so-called hallmarks of cancer, which will be discussed in the following chapter.  
1.4.2 TGF- signaling and the hallmarks of cancer 
The complex and necessary steps of cancer formation and progression are described as 
hallmarks of cancers (outlined in [165, 166]). TGF- may play important roles in all of them 
(Figure 1.7; summarized in [167]): 
Resistance to growth limiting factors and evasion of apoptosis  
Under normal circumstances, inhibition of proliferation and induction of programmed cell 
death are important features to keep tissue homeostasis and healthy cells, e.g., without 
damaged DNA. Among others, TGF- is an important regulator of tissue homeostasis. 
Cancer cells are usually resistant against such signals. Thus, many tumors develop 
strategies to inhibit TGF- signaling as a whole or exclusively the cytostatic TGF- branch.  
To avoid cytostatic effects of TGF-, aberrations in TGF- receptors and common-mediator 
Smad4 were found in different tumors (reviewed in [163]). Mutational inactivation of TRII or 
a decrease of TRI and TRII expression was found in various cancers (reviewed [149]). 
Carriers of a common hypomorphic TRI allele (TGFBR1*6A) have a 20-40% higher risk to 
suffer from breast, ovarian or colorectal cancer [168]. Mutations in receptor Smads are 
detected rather seldom. However, Smad2 is mutated in a subset of colorectal cancers [169] 
whereas Smad3 expression is lost in gastric cancers and T cell lymphoblastic leukemia 
[149]. In contrast to R-Smads, Smad4 is a well recognized tumor suppressor, which is 
underrepresented in a few cancers, e.g., pancreatic carcinomas (55%) [170] and sporadic 
colorectal tumors [169]. In some tumors, underlying mechanisms of TGF- resistance are 
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well defined (aberrations in Smad4 and TRII). Nevertheless, there are still a broad number 
of cases, for which the mechanism is not yet understood. Different findings suggest, as a 
beneficial event, an upregulation of inhibitors Smad7 (chapter 1.4.3), Ski or SnoN  [57, 171] 
or the inhibition of TGF- signaling by pro-tumorigenic factors, e.g., c-Myc [172], mutated p53 
[136] or Ras [78].  
Depletion of Smad4 occurs in about 10% and downregulation of TRII in a subset of 25% of 
HCCs [173, 174]. However, mutations in TGF- signaling components, such as Smad4 and 
Smad2, are rather scarce in HCC when compared to other cancers. Nevertheless, aberrant 
TGF- signaling is frequently observed in HCC [175], suggesting other mechanisms 
underlying the observed dysregulation. For example, induction of the PI3K/Akt pathway, an 
important mediator of proliferation and survival, inhibits TGF- mediated apoptosis in the 
HCC cell line Hep3B [176]. Independent of its kinase activity, Akt binds Smad3 and prevents 
its activation by TGF-. However, this complex formation is inhibited by TGF- itself, so that 
the balance between Akt and Smad3 decides over the cell fate [177, 178]. In line with this, 
Akt is frequently overexpressed and hyperactive in HCC [179, 180]. Smad7 is overexpressed 
in a limited number of HCCs [159, 181] and is able to protect HCC cell line Hep3B against 
cytostatic effects of TGF- [116]. Finally, ELF (embryonic liver beta-fodrin) and PRAJA 
(PJA1) provide another possible mechanism to establish resistance against cytostatic effects 
of TGF-. ELF interacts with Smad3, but not Smad2, and guides it into the nucleus. PRAJA, 
an E3 ligase, marks ELF and Smad3 but not Smad4 for its proteasomal degradation [182, 
183]. Aberrant levels of those two components may therefore build up the cytostatic 
resistance. In fact, ELF is underrepresented in HCC [184].    
Proliferation despite missing exogenous growth factors  
Tumors develop an independency of exogenous growth signals by autonomous production of 
mitogenic proteins or by constitutive activation of corresponding signal cascades. TGF- was 
named after its ability to induce proliferation as well as transformation of mesenchymal cells 
[185]. However, in epithelial, endothelial and hematopoietic cells, its antiproliferative effects 
are well known (chapter 1.2). Similar to mesenchymal cells, TGF- was found to induce 
proliferation in some cancer cell lines of epithelial origin, e.g., prostate cancer [186] and HCC 
cell lines HCC-M and HCC-T [187] suggesting that tumors of epithelial origin may even invert 
cytostatic TGF- effects. One underlying reason might be the capability of TGF- to elevate 
the production of mitogenic growth factors (e.g., PDGF [188] and FGF [189]) and some of 
their receptors, e.g., PDGF receptor [188]. Next to a direct impact on various growth factors, 
TGF- is known to activate Smad independent pathways (chapter 1.1.3 and 1.1.4), e.g., the 
mitogenic branch of Ras-Raf-MAPK pathway, a mediator of different growth factors, e.g., 
EGF and FGF [190]. 
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Capability of invasion and migration  
Tumor aggressiveness is increased by migration, invasion and metastasizing to surrounding 
tissue and, more importantly, to more distant sites. To acquire those abilities, several events 
have to take place in a cell and TGF- may be involved: TGF- loosens (epithelial) cell-cell 
contacts by initiating EMT (chapter 1.2). Coherently, blockage of TGF- leads to an increase 
of epithelial marker E-cadherin and inhibition of migration and invasion in highly invasive 
HCC cell lines [191]. Additionally, TGF- induces expression of 31-integrin and thereby 
transforms HCC cell line HepG2 to a migrative and invasive cell line under certain 
circumstances. Integrins are transmembrane receptors which are involved in processes such 
as adhesion, migration, invasion, proliferation and survival [192]. TGF- may enhance levels 
of extracellular matrix proteins, e.g., collagen. Further, it inhibits the expression of matrix 
degrading enzymes such as collagenase, while it induces the expression of their inhibitors, 
PAI-1 and TIMP-1, amongst others [139, 162]. During tumorigenesis, this feature may 
change and, suddenly, TGF- even enhances levels of matrix-degrading proteins, e.g., 
protease uPA (urokinase-type plasminogen activator) [193]. Hence, TGF- possibly 
increases tumorigenicity by dissolving cell-cell-contacts and enhancing proteolytic activity 
and thereby facilitates enhanced cell motility.  
Figure 1.7 Hallmarks of cancer and involvement of TGF- in it (inspired by [165-167]. 
Introduction  18 
Induction of angiogenesis and creation of access to blood supply  
To increase sizes of solid tumors, an access to the blood system is needed to grant supply of 
nutrients and oxygen. TGF- is involved in the regulation of angiogenesis, the formation of 
new blood vessels, and was shown to be pro-angiogenic in vivo. Knockdown of TGF-
signaling components, such as TGF- [194] or TRI [195] leads to defective vessel formation 
in mouse models. In human, the relevance of TGF- for angiogenesis was demonstrated by 
the correlation of TGF- receptor endoglin mutations with hereditary hemorrhagic 
telangiectasia, a genetic disease which is based on aberrant blood vessel formation [196]. 
Accordingly, TGF- has been linked to tumor vascularity in HCC [197].
Circumvention of limited cell divisions 
Mature somatic cells usually exhibit, based on inactive telomerase and therefore telomere 
shortening during each mitotic cycle, a limited life span. Reaching immortality by resetting 
this “mitotic clock” is a crucial step during the conversion of a normal cell to a neoplastic one. 
One approach of normal cells to inhibit telomerase activity is to contain expression of human 
telomerase reverse transcriptase (hTERT), the catalytic and rate limiting subunit of human 
telomerase. In cancers, including HCC, telomerase activity and hTERT expression is usually 
increased [198-200] to maintain protective chromosome ends despite enhanced cell division. 
TGF- is a potent inhibitor of hTERT expression [201]. Hence, TGF- may exert its tumor 
suppressive effects by restricting hTERT expression and activity. Cancer cells could benefit 
from interference with those mechanisms.   
Evasion of attack by the immune system  
The expression of tumor-specific antigens on the cell surface would normally lead to the 
recognition and destruction of tumor cells by the immune system. Most cancer cells evade 
this attack through various mechanisms. Regarding the immune response, TGF- mainly 
exerts anti-inflammatory functions (outlined in [104]). Its importance as key regulator of 
immune and inflammatory processes was demonstrated in a TGF-1 knockout mouse [202]. 
In line with this, TGF- levels are elevated in various cancers [154-156, 203] including HCC 
[158, 159], possibly also to overcome immune surveillance. Interestingly, elevated TGF-
levels are often observed in T cell leukemia, which is frequently accompanied by disturbed 
cellular immunity [153]. These findings indicate that increased TGF- levels within neoplastic 
areas eventually contribute to building up protection against the immune system. Noteworthy, 
there is accumulating evidence of a pro-tumorigenic cancer-associated inflammation.  
“Genome instability” 
There are different intracellular processes which control genomic integrity and repair possible 
defects. Aberrations in one of those processes, sooner or later, lead to an enrichment of 
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genomic mutations. Tumor cells usually show defects in some of those genome monitoring 
processes. Radiation induced apoptosis and p53 activity (an important protein for the 
regulation of cell cycle, DNA repair and apoptosis) are reduced in heterozygous TGF-
knockout mice [204]. However, p53 mutation is a frequent motif in tumors. On the contrary, 
TGF- inhibits DNA repair in epithelial cells through downregulation of Rad51, a component 
of a DNA repair complex. This suggests that TGF- is able to inhibit DNA repair and might 
therefore promote genomic instability [205]. An increased mutation rate accelerates the 
formation of a phenotype with advantages over healthy cells. Hence, this genomic instability 
is a basic requirement to facilitate the above described hallmarks of cancer. 
1.4.3 The role of Smad7 during cancerogenesis  
In line with the ambiguous functions of TGF- during tumorigenesis and different outcomes in 
different cancers, Smad7 shows similar double edged behavior in various cancers. 
Smad7 as a tumor suppressor 
Smad7, accompanied by INF- induction, promotes colitis but protects against colitis 
associated colorectal cancer in a Smad7 overexpressing mouse model [206]. Similarly, 
Smad7 was observed to block invasion of murine mammary carcinoma cell line JygMC to 
liver or lung in vivo, accompanied by an increase of -Catenin and E-Cadherin expression 
[120]. In human patients with esophageal squamous cell carcinoma, low Smad7 expression 
correlated with metastasis and a poorer prognosis [207]. 
Smad7 as an oncogene 
Smad7 may exert pro-tumorigenic functions in a broad range of different cancers: Colorectal 
cancer patients with a Smad7 deletion have a better prognosis [208], which is in line with 
enhanced metastasis of Smad7 overexpressing human colorectal cancer cell lines in mouse 
[209]. However, another publication showed an opposite but not significant result in patients 
[156]. Further, elevated Smad7 can be associated with poorer prognosis for patients with 
endometrial or gastric cancer [210, 211]. Chen et al. demonstrated that Smad7 protein levels 
increase with ascending malignant transformation of oral epithelium [212]. Similarly, Smad7 
seems to correlate with a more aggressive phenotype in invasive breast cancers [213, 214]. 
In thyroid tumors, Smad7 staining intensifies during tumor formation and even more during 
malignant transformation [215]. Furthermore, Smad7 overexpression in mouse airway Clara 
cells protects against asthma but promotes chemically induced lung cancer [216]. 
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Smad7 with possible dual roles during cancerogenesis 
In some cancers, the role of Smad7 is still not fully clarified. In pancreatic cancer, for 
example, Smad7 was identified as a tumor suppressor, as undetectable Smad7 protein 
levels correlated with metastasis and poorer prognosis [217]. In contradiction, Kleeff et al 
found that Smad7 mRNA (messenger RNA) is elevated in human pancreatic cancer tissue 
samples. Smad7 protects pancreatic cancer cells against TGF- induced growth arrest 
without blocking PAI-1 induction in vitro and enhances tumor growth in vivo [218]Smad7 
levels are elevated in human skin areas exposed to sun light [219] suggesting a possible 
oncogenic role of Smad7 of neoplastic skin diseases. Additionally, Smad7 in combination 
with oncogene Ras, but not alone, induces malignant transformation of keratinocytes in vitro
and in vivo [220]. On the other hand, it has to be noted that DiVito et al show a tumor 
suppressive effect of Smad7 in a melanoma cell line in vitro and in vivo [122]. In HCC, 
Smad7 staining was more present in neoplastic tissue when compared to adjacent areas 
[159, 181]. However, the inhibitor was found to inhibit -catenin activation and nuclear 
translocation as well as HCC promotion in a mouse model [121]. 
1.5 Aims of this study 
HCC is the third most common cause for cancer related deaths with limited treatment 
options. Because TGF- signaling is frequently aberrant in HCC, it is an attractive and 
intensively studied, but so far seldom used, therapeutic target. The mechanistic elucidation of 
TGF- signaling in HCC is still insufficient because of its ambiguous nature. Yet, to develop a 
deep understanding of TGF- signaling in a context, stage and time dependent manner is 
indispensable. This alone will prevent from targeting a wrong TGF- signaling component at 
the wrong moment and will facilitate the design of individual adjusted therapy strategies.  
This study thus aimed to characterize TGF- signaling in ten commonly used liver cancer cell 
lines, and to identify possible correlations to the cytostatic behavior. TGF- induces growth 
arrest and apoptosis in hepatocytes, which is often disrupted in HCC. Hence, effects of 
TGF- on proliferation and cell death were analyzed to identify resistant and responsive cell 
lines. Basal and TGF- induced expression of TGF- signaling components were evaluated 
to detect possible underlying reasons for different cytostatic responses. TGF- signaling can 
be disrupted at different levels. Therefore, TGF- induced R-Smad phosphorylation and the 
resulting transcriptional activity and target gene expression were analyzed to elucidate the 
position of signaling disruption. Furthermore, knockdown experiments aimed to work out the 
impact of Smad2 and 3 on observed cytostatic effects of TGF-. Finally, a possible 
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involvement of different described protective mechanisms (inhibitory Smad7, Akt and other 
survival factors, PRAJA/ELF) against TGF- induced cell death was examined.  
Smad7 may interfere with TGF- mediated cytostasis and is frequently overexpressed in 
cancer. Hence, the Smad7 expression levels in human HCC were of interest. 
This study offers an in-depth analysis of canonical TGF- signaling in HCC and 
hepatoblastoma cell lines and associates different phenotypes with resistance or 
responsiveness towards cytostatic effects of TGF-.  
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2 MATERIALS AND METHODS
2.1 Materials 
2.1.1 Instruments 
Agarose gel electrophoresis system   Peqlab Biotechnology (Erlangen, Germany) 
 PerfectBlueTM Mini & Midi System 
Blotting module, XCell II Blot  Invitrogen GmbH (Darmstadt, Germany) 
Cell culture incubator, HERAcell Kendro Laboratory (Hanau, Germany)  
Centrifuges 
 Biofuge Primo R Heraeus Holding (Solingen, Germany) 
 Biofuge Fresco Heraeus Holding (Solingen, Germany)
Electrophoresis module, Mini-Protean Bio-Rad Laboratories (Munich, Germany) 
Gel casting system for immunoblot, Bio-Rad Laboratories ( Munich, Germany) 
 Mini-Protean  
Laminar flow hood, HA 2472 GS Heraeus Holding (Solingen, Germany) 
Luminescent image analyzer,  Peqlab Biotechnology (Erlangen, Germany) 
 FUSION SL™ Advance  
Microplate reader Infinite® M200  Tecan Group Ltd. (Männedorf, Switzerland) 
NanoQuant plate Tecan Group Ltd. (Männedorf, Switzerland) 
PCR thermocycler, DNA engine Dyad® Bio-Rad Laboratories (München, Germany) 
Shaker, Duomax1030 Heidolph (Schwabach, Germany)  
Real time PCR cylcer AbiPrism7000 Applied Biosystems (Foster City, CA, USA) 
Ultra-TurraxT25  IKA®-Werke (Staufen, Germany) 
UV transilluminator INTAS (Göttingen, Germany) 
2.1.2 Chemicals 
Acrylamide/Bis Solution, 37.5:1 (30% w/v) Serva (Heidelberg, Germany) 
Ammonium persulfate (APS) Sigma Aldrich (St. Louis, Missouri, USA)  
Bromphenol blue, sodium salt Applichem (Darmstadt, Germany) 
Chloroform Sigma Aldrich (St. Louis, Missouri, USA) 
p-Coumaric acid Sigma Aldrich (St. Louis, Missouri, USA) 
Deoxycholic acid, sodium salt Serva (Heidelberg, Germany) 
Diethyl pyrocarbonate (DEPC), 99% Sigma Aldrich (St. Louis, Missouri, USA) 
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3-(4,5-Dimethylthiazol-2-yl)-2,5-  Sigma Aldrich (St. Louis, Missouri, USA) 
 diphenyltetrazolium bromide  
Dimethyl sulfoxide, suitable for hybridoma Sigma Aldrich (St. Louis, Missouri, USA) 
Dimethyl sulfoxide (DMSO), 99.5% Sigma Aldrich (St. Louis, Missouri, USA) 
Dimethyl sulfoxide, suitable for hybridoma Sigma Aldrich (St. Louis, Missouri, USA) 
EDTA, disodium salt Carl Roth (Karlsruhe, Germany) 
Ethanol, 99% Merck (Darmstadt, Germany) 
Ethidium bromide Sigma Aldrich (St. Louis, Missouri, USA) 
Ficoll solution Sigma Aldrich (St. Louis, Missouri, USA) 
Formaldehyd Sigma Aldrich (St. Louis, Missouri, USA) 
Formamid Merck Group (Darmstadt, Germany) 
Glacial acetic acid Merck Group (Darmstadt, Germany) 
Glycerol Sigma Aldrich (St. Louis, Missouri, USA) 
Glycine Merck (Darmstadt, Germany) 
Hydrochloric acid (HCl), 1N  Merck (Darmstadt, Germany) 
Hydrogen peroxide solution, 30%  Merck (Darmstadt, Germany) 
Isopropanol Merck (Darmstadt, Germany) 
Luminol Sigma Aldrich (St. Louis, Missouri, USA) 
Magnesium chloride solution, 1M, Sigma Aldrich (St. Louis, Missouri, USA) 
 for molecular biology 
-Mercaptoethanol Merck (Darmstadt, Germany) 
MOPS, buffer grade Applichem (Darmstadt, Germany) 
4-Nitrophenyl phosphate disodium  Sigma Aldrich (St. Louis, Missouri, USA) 
 salt hexahydrate 
Nonident P40 Roche (Mannheim, Germany) 
SDS (sodium dodecyl sulfate), ultra pure Carl Roth (Karlsruhe, Germany) 
Sodium acetate trihydrate Merck Group (Darmstadt, Germany) 
Sodium hydroxide (NaOH), 1N  Merck Group (Darmstadt, Germany)  
Sodium chloride (NaCl) Carl Roth (Karlsruhe, Germany) 
TEMED  Sigma Aldrich (St. Louis, Missouri, USA) 
 (N,N,N',N'-Tetramethylethylene-diamine)  
Trypan blue solution Sigma Aldrich (St. Louis, Missouri, USA) 
Universal-Agarose "Seakem LE" Lonza Group (Cologne, Germany) 
Tris(hydroxymethyl)aminomethane (Tris base) Sigma Aldrich (St. Louis, Missouri, USA) 
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2.1.3 Cell culture  
2.1.3.1 Cell lines 
For the cell culture experiments, ten different liver cancer cell lines and the reporter cell line 
MFB-F11 were used.  
HCC-M HCC-M cells were established and first described in 1983 [221]. This cell 
line of epithelial phenotype was isolated from a hepatocellular carcinoma 
(Edmondson type III) of a Hepatitis B surface antigen (HBsAG)-positive 
Japanese male. Injected in nude mice, tumors of this type of hepatocellular 
carcinoma developed at the sites of inoculation. HBV particles or HBsAg 
could not be detected in the cell culture.  
HCC-T This human hepatoma cell line was isolated from a male Japanese HCC 
patient (Edmondson type II) with cirrhosis and Hepatitis C virus infection 
(HCV) [222]. HCC-T cells show epithelial like morphology and features of 
malignant cells such as tumor development in nude mice.  
HepG2 Epithelial HepG2 cells derive from a well differentiated HCC of a 15 year 
old male Caucasian from Argentina [223]. 
Hep3B This cell line was isolated from a well differentiated HCC from an 8 year old 
back male from the U.S.A. This cell line, when injected into nude mice, 
forms tumors of hepatocelluar character [223, 224].
HuH6 HuH6 cells are epithelial like cells deriving from a hepatoblastoma of a 
Japanese infant [225]. 
HuH7 This cell line was established from a well differentiated and serologically 
negative HCC, removed from a 57-year old Japanese male [226].   
PLC/PRF/5 PLC/PRF/5 or Alexander is a well differentiated HCC cell line obtained from 
an HCC of a 24 year old male patient from Mozambique with cirrhosis and 
HBV infection. It produces HBsAG and forms tumors in nude mice 
[224, 227]. 
FLC-4 This cell line is a mutant of the HCC cell line JHH-4, which was established 
from a 51-year old Japanese male with HCC of Edmondson’s type III. 
FLC-4 cells are well differentiated and secrete liver-specific proteins [228]. 
They show similar morphological and biological properties to its parental 
cell line JHH-4, which was established from a hepatocellular carcinoma of 
the Edmondson type III, and which forms tumors in nude mice [229].  
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HLE and HLF HLE and HLF are two poorly differentiated cell lines, obtained from a HCC 
of a 68-year-old patient. While HLE cells show epithelial-like morphology, 
HLF cells are rather similar to fibroblasts. Nevertheless, it is supposed that 
the latter also originates from hepatoma cells. Unlike HLF, HLE cells 
produce -fetoprotein. HLF, but not HLE cells form tumors upon 
transplantation into the cheek pouch of adult hamsters treated with 
cortisone acetate [230]. 
MFB-F11 MFB-F11 is a murine fibroblast cell line from TGF--/- mice and expresses 
an introduced alkaline phosphatase under the control of Smad binding 
elements (SBE). Hence, it is used as reporter cell line for TGF-1-3 
quantification [231]. 
Cell lines were kindly provided by: Prof. Tetsu Watanabe and Prof. Yutaka Inagaki, Tokai 
University School of Medicine Basic Clinical Sciences and Public Health, Kanagawa, Japan 
(HCC-M and HCC-T); the SFB/TTR77 funded by the Deutsche Forschungsgemeinschaft 
(HepG2, Hep3B, PLC/PRF/5, HLE and HLF purchased from ATCC (American Type Culture 
Collection) and HuH7 purchased from JCRB (Japanese Collection of Research Bioresources 
Cell Bank)) and Prof. Michael Kern, Institute of Pathology, Cologne, Germany (FLC-4 and 
HuH6). 
2.1.3.2 Cell culture reagents and additives 
Dulbecco’s Modified Eagle Medium (DMEM) Lonza Group Ltd. (Cologne, Germany) 
 with high glucose , without L-glutamine  
Dulbecco’s Modified Eagle Medium (DMEM) Lonza Group Ltd. (Cologne, Germany) 
 with high glucose , without L-glutamine, 
 without phenol red  
L-glutamine, 200mM PAA Laboratories (Cölbe, Germany) 
Fetal bovine serum (FBS) Invitrogen (Darmstadt, Germany) 
Hank's Buffered Salt Solution (HBSS) PAA Laboratories (Cölbe, Germany) 
10xTrypsin-EDTA PAA Laboratories (Cölbe, Germany) 
Human recombinant TGF-1 Peprotech (Hamburg, Germany) 
Hygromycin B Sigma Aldrich (St. Louis, Missouri, USA) 
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2.1.3.3 Materials for RNA interference, transfection and adenoviral infection 
technology 
Reagents for transfection and siRNA knockdown
Lipofectamine®2000 Transfection Reagent Invitrogen (Darmstadt, Germany) 
Lipofectamine®RNAiMax Invitrogen (Darmstadt, Germany) 
Opti-MEM® reduced serum medium Invitrogen (Darmstadt, Germany) 
siRNA oligonucleotides
Target gene Company Order No 
negative control 
Qiagen 
1027281 
Smad2 SI02757496 
Smad3 SI00082495 
Table 2.1 siRNAs used in this study. All siRNAs were obtained from Qiagen (Hilden, Germany) 
Plasmids
-galactosidase control vector, pCR3lacZ Invitrogen (Darmstadt, Germany) 
Smad7 promoter deletion mutant,  described in [37] 
 p(-625 SacI)-Smad7 prom-Luc  
pARE-Luc and Fast-1 gift from Prof. C.-H. Heldin (Ludwig Institute  
   for Cancer Research, Uppsala University,  
 Uppsala, Sweden) [232]  
Adenoviruses
Ad(CAGA)9-MLP-Luc  described in [31] 
-galactosidase control adenovirus  gift from Prof. C.-H. Heldin (Ludwig Institute  
   for Cancer Research, Uppsala University,  
   Uppsala, Sweden), described in [233] 
Reagents for reporter assays
Passive lysis buffer Promega (Mannheim, Germany) 
-galactosidase assay Promega (Mannheim, Germany) 
Luciferase substrate  Promega (Mannheim, Germany) 
2.1.3.4 Reagents for MTT, LDH and ATP and alkaline phosphatase assays 
MTT solution
5mg/mL  MTT powder (3-(4,5-Dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide)  
Dissolved in DMEM starvation medium, sterile filtered and stored at -20°C  
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MTT solvent
4mL  10% SDS in double distilled water (ddH2O) 
4mL DMSO  
2mL Acetic acid solution (1.2mL glacial acetic acid in 100mL ddH2O) 
Freshly prepared 
AP buffer
3.75g  Glycine (50mM) 
12.11g Tris base (100mM) 
1mL  Magnesium chloride (MgCl2) solution, 1M (1mM) 
Adjusted to pH 10.5 with NaOH and filled up with ddH2O to 1L 
AP substrate solution
2mg 4-Nitrophenyl phosphate disodium salt hexahydrate  
1mL AP-Puffer (see above) 
Freshly prepared 
Cytotoxicity Detection Kit   Roche (Mannheim, Germany) 
Bovine serum albumin, Fraction V (BSA) Merck (Darmstadt, Germany) 
CellTiter-Glo Luminescent Cell Viability Assay  Promega (Mannheim, Germany) 
2.1.4 Materials for DNA and RNA work 
2.1.4.1 Kits, buffers and reagents for RNA isolation, reverse transcription, PCR and 
gel electrophoresis 
Taq DNA polymerase, FastStart, dNTP Pack Roche Diagnostics (Mannheim, Germany) 
Omnitect Reverse Transcription Kit  Qiagen (Hilden, Germany) 
RNeasy Mini Kit  Qiagen, Hilden, Germany 
TRIzol® Reagent Invitrogen (Darmstadt, Germany) 
DNA ladder, 100bp plus  AppliChem (Darmstadt, Germany) 
50x TAE buffer
242g  Tris base 
57.1mL  Glacial acetic acid 
18.6g  EDTA, sodium salt 
Adjusted with ddH2O to 1L 
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DNA loading buffer 
35mL Glycerol 
2 mL 50xTAE buffer 
Filled up with ddH2O to 100 mL, addition of a spatula tip of bromphenol blue 
DEPC-water
1mL Diethyl pyrocarbonate (DEPC) 
Adjusted with ddH2O to 1L; incubated at room temperature over night; autoclaved for 20min. 
20x MOPS (RNA running buffer)  
400mM  MOPS 
100mM  Sodium acetate trihydrate 
20mM  EDTA, disodium salt 
In DEPC-water, pH 7.0  
RNA loading buffer
50%  Formamide    
22mM  Formaldehyde   
5% 20x MOPS buffer    
10%  Ficoll solution 
In DEPC water; addition of 6 µL/mL ethidium bromide and 1 spatula tip of bromphenol blue 
  
2.1.4.2 Human gene expression assays and primers for TaqMan and SYBR Green real 
time PCR  
Gene Assay name Assay ID (Applied Biosystems) 
Smad2 Smad2 Hs00998181_gH 
Smad3 Smad3 Hs00969205_g1 
Smad7 Smad7 Hs00178696_m1 
TGF- receptor 1 TGFBR1 Hs00610318_m1 
TGF- receptor 2 TGFBR2 Hs00559661_m1 
18S 18S-rRNA Hs03003631_g1 
B2M beta-2-microglobulin Hs00187842_m1 
Table 2.2 TaqMan gene expression assays used in this study. All assays were obtained from Applied 
Biosystems (Foster City, CA, USA) and were specific for the respective human mRNA.     
2x TaqMan® Universal PCR Master Mix Applied Biosystems (Foster City, CA, USA) 
 No AmpErase® UNG 
2x SYBR® Green Master Mix Applied Biosystems (Foster City, CA, USA) 
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Gene Forward primer (5’3’) Reverse primer (5’3’) 
PRAJA TCGCCATTTTCCACTACTCGT GTTCCCGAACTCTCGCTGT 
ELF AGCTGGAAGGCAGATTCAAG CGTCCATCTCGAAGGTCAGT 
Bim TAAGTTCTGAGTGTGACCGAGA GCTCTGTCTGTAGGGAGGTAGG 
PAI-1 CACAAATCAGACGGCAGCACT CATCGGGCGTGGTGAACTC 
Smad4 GCTGCTGGAATTGGTGTTGATG AGGTGTTTCTTTGATGCTCTGTCT 
18S AAACGGCTACCACATCCAAG CCTCCAATGGATCCTCGTTA 
Table 2.3 Primer sets for gene specific SYBR Green real time PCR.   
2.1.5 Materials for SDS-PAGE gel electrophoresis and immunoblot analysis 
2.1.5.1 Buffers and solutions for protein lysis and determination of concentration  
RIPA buffer (Cell lysis buffer)
1,815g Tris base  
4.383g Sodium chloride (NaCL)  
6mL Nonident P40  
0.279g EDTA, sodium salt 
0.3g SDS  
1.6g Deoxycholic acid, sodium salt 
1x  Protease inhibitor (see below) 
Adjusted with ddH2O to 300mL, pH7.2; stored at -20°C;  
Addition of 1x phosphatase inhibitor (see below) immediately prior use 
Phosphatase Inhibitor Cocktail 2 Sigma Aldrich (St. Louis, Missouri, USA) 
Protease Inhibitor, Complete Roche (Mannheim, Germany) 
Bovine serum albumin, Fraction V (BSA) Merck (Darmstadt, Germany) 
Protein Assay, DC Bio-Rad (Munich, Germany) 
2.1.5.2 Buffers, reagents and materials for SDS-PAGE gel electrophoresis and 
immunoblot analysis 
10x Lämmli buffer
144g  Glycine 
30.34g  Tris base (for electorphoresis) 
100mL  10% SDS (for electrophoresis) 
Adjusted with ddH2O to 1L 
Materials and Methods  30 
1x Lämmli buffer
100mL  10x Lämmli buffer 
900mL ddH2O 
Lämmli loading buffer, 5x
2.5mL  -Mercaptoethanol  
2g  SDS  
10mg  Bromphenol blue 
6mL  Tris-HCl (hydrochloric acid), 1M, pH6.8  
200µL  EDTA, 500mM  
10mL  Glycerin  
1.3mL  ddH2O 
10xTowbin transfer buffer
250mM Tris base 
1.920M Glycine 
Adjusted with ddH2O to 1L 
0.5x Towbin transfer buffer
50mL 10x Towbin transfer buffer 
200mL Methanol 
Filled up with ddH2O to 1L 
Protein ladder, PageRuler Plus prestained Fermentas (St. Leon-Rot, Germany) 
Nitrocellulose membrane, 0.45micron Pierce (Rockford, IL, USA) 
Chromatography paper, 3MM Chr Whatmann (Maidstone, England) 
Sponge blotting pads Invitrogen (Darmstadt, Germany)  
2.1.5.3 Antibodies, buffers and reagents for protein detection 
10xTBS
12.1g Tris base 
87.66g Sodium chloride (NaCl) 
Adjusted to pH7.6 and filled up with ddH2O to 1L 
TBST  
100mL 10xTBS 
10mL 10% Tween20 solution (in ddH2O) 
Filled up with ddH2O to 1L 
Materials and Methods  31 
Epitope (target) Species Company Cat.No Dilution 
Primary antibodies 
Akt rabbit Cell Signaling 9272 1:1000 
Phospho-Akt (Ser473) (587F11) mouse Cell Signaling 4051 1:500 
Bcl-2 (50E3) rabbit Cell Signaling 2870 1:1000 
Bcl-XL (54H6) rabbit Cell Signaling 2764 1:1000 
Phospho-c-Jun (Ser63) rabbit Cell Signaling 9261 1:1000 
c-Myc (2Q329)  mouse Santa Cruz sc-70464 1:500 
Cleaved Caspase-3 (Asp175) (5A1E) rabbit Cell Signaling 9664 1:1000 
E-Cadherin mouse BD Bioscience 610181 1:1000 
Phospho-ERK (E-4) mouse Santa Cruz sc-7383 1:1000 
GAPDH rabbit Santa Cruz sc-25778 1:2000 
p21WAF1/Cip1 (CP74)   mouse Sigma Aldrich P1484 1:1000 
Phospho-p38 MAPK (Thr180/Tyr182) rabbit Cell Signaling 4631 1:1000 
PARP rabbit Cell Signaling 9542 1:1000 
PCNA (F-2) mouse Santa Cruz sc-25280 1:1000 
Smad2 (D43B4) rabbit Cell Signaling 5339 1:1000 
Phospho-Smad2 (Ser465/467)   rabbit Cell Signaling 3101 1:1000 
Smad3 rabbit Cell Signaling 9513 1:1000 
Phospho-Smad3 rabbit Epitomics 1880-1 1:1000 
Smad4 (B-8) mouse Santa Cruz sc-7966 1:1000 
Secondary antibodies – horseradish peroxidase (HRP) conjugated 
goat anti-rabbit IgG-HRP goat Santa Cruz sc-2301 1:10000 
goat anti-mouse IgG-HRP goat Santa Cruz sc-2005 1:10000 
Table 2.4 Primary and secondary antibodies used for immunoblot analysis. Antibodies were obtained 
from Cell Signaling (Danvers, MA, USA), Santa Cruz Biotechnology (Santa Cruz, California, USA.), 
Sigma Aldrich (St. Louis, Missouri, USA), BD Bioscience (Heidelberg, Germany) or Epitomics 
(Burlingame, California, USA) 
Ponceau S Red Sigma Aldrich (St. Louis, Missouri, USA) 
ECL solution
10mL 0.1M Tris-HCl buffer (pH=8.5) 
50µL 250mM Luminol 
22µL 90 mM p-Coumaric acid 
3µL Hydrogen peroxide solution 30%  
Freshly prepared  
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2.2 Methods 
2.2.1 Cell Culture 
All cell culture work was performed under sterile conditions using a laminar flow hood.  
  
2.2.1.1 Cell Culture 
Ten different liver cancer cell lines (chapter 2.1.3.1) and MFB-F11 cells were maintained in 
growth medium. Cells were cultured in filter cap tissue culture flasks at 37 °C in a humidified 
incubator with 5% CO2. Growth medium comprised high glucose DMEM medium, 2mM 
L-glutamine and 10% FBS and, in the case of MFB-F11 cells, 15µg/mL hygromycin B. Cells 
were subcultured before reaching full confluency. For this, cells were washed with HBSS and 
collected in growth medium after detachment with 1xTypsin-EDTA. An appropriate amount 
of cells was used for further culturing or experiments. For experiments, cell numbers were 
determined using a Boyden chamber. Dead cells were identified using Trypan blue solution 
and ignored during cell counting.  
2.2.1.2 Cryopreservation of cell lines 
For long term storage, cells of a low passage number were collected (chapter 2.2.1.1) in 
growth medium, spun down (250xg, 5min, room temperature) and resuspended in ice cold 
growth medium supplemented with 10% dimethyl sulfoxide (DMSO, suitable for hybridoma). 
Cells were stored in cryo tubes at -20°C for 4h, kept at -80°C over night and finally stored in 
liquid nitrogen. These cryopreserved cells were thawed at regular intervals to perform 
experiments within a similar passage range. For this, cell in cryo tubes were warmed to 37°C 
in a water bath and immediately transferred to warm medium, spun down (250xg, 5min) and 
resuspended in growth medium.    
2.2.1.3 Mycoplasma detection 
Each cell culture was tested for mycoplasma contamination at a low and high passage 
number, using the VenorGEM Mycoplasma Kit according to manufacturer’s protocol. Briefly, 
cell culture supernatant was incubated at 95°C for 5min and cell debris was  removed by 
centrifugation (13000rpm, 5s). The test is a PCR (polymerase chain reaction) based 
detection of mycoplasma 16S RNA and includes an internal and a positive control to ensure 
a successful PCR. Together with the internal control DNA, cell culture supernatant or the 
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positive control was used to perform a PCR with the following conditions: 1cycle at  94°C for 
2min, 39cycles at 94°C for 30s, 55°C for 30s and 72°C for 30s. PCR products were 
detected as described in 2.2.4.4. Mycoplasma negative samples resulted in one signal 
(internal control, 191 bp), while contaminated samples or the positive control showed a 
second signal at 265-278bp (Figure 2.1).   
Figure 2.1 PCR for detection of mycoplasma contamination. Four examples of tested supernatants of HCC 
cultures are shown as well as the positive (Co+) and negative (Co-) controls.  
2.2.2 Cell culture experiments 
If not stated otherwise, cell line experiments were conducted in starvation medium (growth 
medium without FBS) and with a final confluency below 70-80%. The cells were stored in the 
cell culture incubator between the different working steps. All experiments were performed 
within a passage number of 3-12 after thawing cryopreserved cells (see chapter 2.2.1.2).  
2.2.2.1 Detection of promoter and transcriptional activity 
2.2.2.1.1 Detection of Smad3/Smad4 reporter activity
To detect TGF- induced Smad3/Smad4 transcriptional activity, an adenoviral construct 
carrying nine CAGA sequence repetitions within the firefly luciferase promoter region 
(Ad(CAGA)9-MLP-Luc, described in [31]) was used for a luciferase promoter assay (hereafter 
named CAGA-Luc assay). 20000cells/cm² were allowed to attach to cell culture plates. Cells 
were then infected with the adenovirus for 2h before washing twice with HBSS and adding 
starvation medium. To ensure equal and efficient infection, the cells were co-infected with an 
adenovirus carrying a -galactosidase construct (described in [233]). The next day, medium 
was replaced with fresh starvation medium either containing 5ng/mL TGF- or not, and cells 
were disrupted in passive lysis buffer 9h later. Each condition was performed in triplicates. 
Cell lysates were transferred to white microtiter plates. After addition of a luciferase 
substrate, luciferase activity was quantified by capturing luminescence with a microplate 
reader. Obtained values were first normalized to -galactosidase activity (see 2.2.2.1.4) of 
the same sample, and afterwards, treated samples were normalized to untreated controls.  
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2.2.2.1.2 Detection of Smad2/Smad4 transcriptional activity   
Unlike Smad3, activated Smad2 is unable to interact with DNA and needs additional 
assistance by, e.g., Fast-1 (chapter 1.1.2, page 3), which then recognizes an activin 
response element (ARE). Hence, a luciferase gene under the control of ARE and Fast-1 
were introduced to cells to evaluate Smad2/Smad4 transcriptional activity. For this, cell lines 
were allowed to attach to a 1cm² growth area over night before switching to 260µL 
starvation medium. The cell confluency was between 70-80 % at that time. 0.3µg ARE, 
0.1µg Fast-1 plasmid as well as 0.05µg -galactosidase control vector in 26µL Opti-MEM 
medium were mixed with 0.4µL Lipofectamine 2000 in 26µL Opti-MEM medium and 
incubated for 20min at room temperature. This mixture was then added dropwise to the cells 
and the transfection reaction was allowed to proceed for 5h before replacing the starvation 
medium. The next day, starvation medium was renewed and either supplemented with 
5ng/mL TGF- or not for 9h, and thereafter, cells were collected in passive lysis buffer. Each 
treatment condition was performed in triplicates and the experiment was evaluated as 
described above. The detection of luciferase and -galactosidase activity is described in 
chapter 2.2.2.1.1 and 2.2.2.1.4.  
  
2.2.2.1.3 Smad7 promoter activity assay
After cell lines attached to a 1.9 cm² growth area, they were cultured in 500µL starvation 
medium over night. Cell density did not exceed 70-80%. For evaluation of Smad7 promoter 
activity, cells were transfected with a functional Smad7 promoter deletion mutant (p(-625 
SacI)-Smad7prom-Luc), which was constructed using the 1321bp rat Smad7 promoter 
region (-1276 to -41) [37]. Smad7 promoter (0.5µg) and -galactosidase (0.2µg) plasmids 
were incubated with 0.8µL Lipofectamine 2000 transfection reagent in 100µL Opti-MEM 
medium for 20min, before dropwise addition to the cell culture wells. After 6h, the 
supernatant was replaced with starvation medium and the next day, cells were either left 
untreated or treated with 5ng/mL TGF- for 6h. Cells were collected in passive lysis buffer. 
Each condition was performed in triplicates. Luciferase and -galactosidase activities were 
evaluated as described in chapter 2.2.2.1.1 and 2.2.2.1.4.  
2.2.2.1.4  -galactosidase activity assay
-galactosidase activity was evaluated using a -galactosidase assay from Promega. 20µL 
cell lysates or passive lysis buffer as a negative control were transferred to a clear microtiter 
plate and incubated with 20µL assay buffer at 37°C until a faint yellow color developed 
(30-60min). Color development was stopped with 60µL 1M sodium carbonate and 
absorption at 420 nm was detected in a microplate reader.  
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2.2.2.2 RNAi knockdown of Smad2 and Smad3 
Hep3B, HuH7 and PLC/PRF/5 cells were cultured in 1cm² wells over night, before replacing 
growth medium with 260µL starvation medium. For knockdown, siRNA (small interfering 
RNA) against Smad2, Smad3 or a non-specific sequence in 26µL Opti-MEM medium was 
mixed with 0.5µL RNAiMax in 26µL Opti-MEM and incubated at room temperature for 
20min. This mix was added dropwise under careful agitation to cell cultures, reaching final 
siRNA concentration of 10nM. Control wells were treated with the same mixture but without 
siRNA. After 6h, starvation medium was replaced and, for HuH7 and PLC/PRF/5, 
supplemented with 1% heat inactivated FBS (hiFBS). Two days later, starvation medium 
was renewed (1% hiFBS for HuH7 cells) and cells were treated with or without 5ng/mL 
TGF- for 72h. Medium for HuH7 contained 1% FBS throughout the experiment, which 
leads to a faster dying out of the siRNA. Hence, a final siRNA concentration of 20nM instead 
of 10nM was applied. Each condition was performed in triplicates. Cell death and 
proliferation rates were evaluated performing a LDH assay as described in chapter 2.2.2.3, 
but with adjusted volumes for cell lysis (260µL). 
Knockdown efficiency was ensured with an immunoblot analysis for (phosphorylated) Smad2 
and 3. For this, cells were disrupted in RIPA buffer after 1h instead of 72h TGF- treatment 
(chapter 2.2.5).  
2.2.2.3 LDH release as an indicator of cell death 
Cell death leads to release of lactate dehydrogenase (LDH), a very stable protein. Hence, it 
can be used for determination of cell death rates. HCC cell lines were seeded in 96well cell 
culture plates and maintained in growth medium over night. After a starvation period of 8h, 
cells were cultured in 100µL starvation medium with or without 5ng/mL TGF-. Medium for 
HCC-M and HuH7 cells was supplemented with 1% hiFBS. After 72h, 50µL of supernatant 
was transferred to a clear microtiter plate. Cell layers were disrupted in 100µL 1%Triton X-
100 in HBSS and 50µL thereof were transferred to the microtiter plate. LDH amount in the 
supernatant and in cell lysates was quantified using a Cytotoxicity Detection Kit. 50µL of a 
catalyst and dye solution mixture (ratio 1:45) was added to each well. Triton buffer and 
starvation medium with 0% or 1% hiFBS served as negative controls. After 10-20min, 
absorption at 490nm was detected with a microplate reader. The percentage of dead cells 
was calculated as follows. The untreated control sample was then defined as zero. 
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For siRNA knockdown experiments (chapter 2.2.2.2), the cytotoxicity assay was additionally 
used to determine the relative amounts of viable cells. For this, the LDH content of viable 
(adherent) cells after TGF- stimulation was normalized to the one without treatment:  
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2.2.2.4 MTT viability assay  
Effects of TGF- on proliferation were analyzed using an MTT viability assay. Cell lines were 
cultured in 0.38cm² (100µL) or 1cm² (250µL) cell culture wells for a 48h or 6day 
experiment, respectively. After attachment, cells were maintained in starvation medium 
containing 0.25% FBS (1% FBS for HCC-M and HuH7) over night and were then either 
treated with 5ng/mL TGF- or not in fresh medium. Starvation medium was supplemented 
with a low amount of FBS because cell lines may need some serum to gain proliferative 
capability. During the 6 day experiment, fresh FBS and TGF- in 50µL medium was added 
3days after start of treatment - using six-fold FBS and TGF- concentrations to reach 
primary concentrations. At the end of the experiment, MTT solution was added at a final 
concentration of 500µg/mL and viable cells were allowed to reduce yellow MTT solution to 
purple formazan crystals for 4h. After removal of the supernatant, formazan crystals were 
resolved with a MTT solvent solution and absorption at 560nm was evaluated using a 
microplate reader. MTT solvent was used as a negative control. The underlying assumption 
of this assay is that the MTT conversion in viable cells is not affected by (TGF-) treatment. 
The effect of TGF- on cell viability was calculated by normalizing data of treated samples to 
corresponding control samples. 
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2.2.2.5 Migration assay 
A transwell assay was performed to analyze migratory capacity of HCC cell lines. Cell lines 
were cultured in cell culture dishes and in medium containing 3% FBS over night. 
Subsequently, cells were starved for 24h (1% hiFBS for HCC-M and HuH7 cells), washed 
with HBSS, detached with 1xTrypsin-EDTA and spun down (200xg, 5min). Single cell 
suspensions with 100000 cells/mL were prepared using starvation medium with 1% BSA. 
Transparent PET transwell cell culture inserts with a pore size of 8µm were transferred to 
24well companion plates, which were filled with 750µL medium containing 10% hiFBS as 
an attractor for motile cells. Bubbles at the bottom of the insert were removed by careful 
tapping before transferring 250µL cell suspension to the transwell inserts. Cell migration was 
allowed for 13h. This was identified as a suitable time period to analyze and compare both, 
highly and less motile cell lines. Each test was performed in triplicates. Cells at the bottom 
and top of the membrane were detached by trypsinization and separately transferred to a 
white 96 well plate. After 10min centrifugation at 500xg, the supernatant was discarded. The 
relative number of migrated (bottom) and non-migrated (top) cells was analyzed adding an 
ATP assay (CellTiter-Glo Assay) to the cells. 10min later, luminescence intensity was 
determined using a microplate reader. The percentage of migrated cells was calculated by 
normalizing the amount of ATP in migrated cells to that in all cells (migrated and non-motile).  
2.2.2.6 Detection of secreted TGF-
TGF- secretion by HCC cell lines was analyzed using the MFB-F11 reporter cell line. This 
cell line was generated by stable transfection of embryonic murine TGF--/- fibroblasts with a 
plasmid carrying the alkaline phosphatase under the control of Smad binding elements (SBE) 
[231]. Stimulation with TGF-1-3 induces expression and secretion of the alkaline 
phosphatase (AP), whose activity can be visualized by addition of the AP substrate p-
nitrophenyl phosphate and its conversion into yellow p-nitrophenol.  
For each HCC cell line, 20000 cells were allowed to attach to 1cm² wells for 4h before 
washing with HBSS twice and adding starvation medium without phenol red. The next day, 
starvation medium was replaced and collected 48h later. Adherent cells were washed with 
HBSS and covered with 60 µL RIPA protein lysis buffer. Protein lysates and conditioned 
medium without cell debris were stored at -80°C until further processing. Protein 
concentration was determined as described in chapter 2.2.5.2. 
50000 MFB-F11 cells/well were allowed to attach to 96well plates for 2h and starvation 
medium without phenol red was added after washing twice with HBSS. The next day, the 
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supernatant was removed to add 50µL fresh phenol red free starvation medium. Each well 
was supplemented with 50µL conditioned medium from the HCC cell lines or with 50µL 
starvation medium containing known TGF- concentrations (0-10ng/mL). Additionally, latent 
TGF- was activated as follows: 50µL of the conditioned medium was incubated with 10µL 
1N hydrochloric acid for 10min before neutralization with 12µL 1N sodium hydroxide. 50µL 
of this mixture was then added to the MFB-F11 cells. Each condition was tested in triplicates. 
MFB-F11 cells were incubated in a cell culture incubator to allow TGF- induced production 
and secretion of alkaline phosphatase. After 48h, 50µL of this medium was transferred to a 
new microtiter plate and supplemented with 50µL AP-substrate-buffer. Absorption of the 
colored product was detected at 420nm at different time points (10min to 3days). 
TGF- concentration in conditioned medium was calculated using the TGF- standard curve. 
A dilution factor was used for medium samples with fully activated TGF-. Total amount of 
TGF- in the supernatant was calculated and afterwards normalized to the total amount of 
protein in adherent cells (TGF- [ng/mgtotal Protein]). 
2.2.3       Patient samples 
Human HCC tissue samples and corresponding non-tumorigenic liver tissue, or RNA isolated 
from matched HCC/non-tumorigenic liver samples were kindly provided by different 
collaboration partners in Germany and China: 
Dr. Thomas Weiß and the Center for Liver Cell Research (Department of Pediatrics and 
Juvenile Medicine, University of Regensburg Hospital, Regensburg, Germany) provided RNA 
samples isolated with a Qiagen-Kit (Hilden, Germany). The samples were collected by the 
Foundation Human Tissue and Cell Research (HTCR) in Regensburg, Germany. The 
experimental procedures were conducted according to the guidelines of the charitable state 
controlled foundation HTCR. All patients provided informed patient's consent, which was 
approved by the local ethical committee of the University of Regensburg.  
Prof. Dr. Otto Kollmar (current address: Department of General and Visceral Surgery, 
University Hospital Göttingen, Göttingen, Germany) and the Department of General, 
Visceral, Vascular and Pediatric Surgery (University of Saarland, Homburg/Saar, Germany) 
provided tissue samples. All patients provided informed consent for tissue procurement, 
which was approved by the local ethics committee. 
Prof. Heike Allgayer and Dr. Jörg Leupold (Department of Experimental Surgery and 
Molecular Oncology of Solid Tumors, Medical Faculty Mannheim, University of Heidelberg 
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and German Cancer Research Center, Heidelberg, Germany) provided tissue samples. 
Tissues were collected from HCC patients at the Department of Surgery (University Hospital 
Mannheim, University of Heidelberg, Germany). All patients gave informed patient's consent 
and the tissue procurement was approved by the local ethical committee.  
Prof. Chun Fang Gao and Dr. Xing Gu (Department of Laboratory Medicine, Eastern 
Hepatobiliary Hospital, Second Military Medical University, Shanghai, China) provided raw 
data of TaqMan real time PCR experiments for Smad7, 18S rRNA and 2-microglobulin. The 
specimens enrolled in this study were collected from September 2007 to December 2008 in 
Shanghai Eastern Hepatobiliary Surgery Hospital (EHBH, Shanghai, China). All patients 
signed informed consents and the experiments were conducted in accordance with the 
official recommendations of the Chinese Community Guidelines.
Immediately after (partial) hepatectomy, tissue samples were snap-frozen in liquid nitrogen 
and stored at -80°C until further procedure. RNA isolation was performed as described in 
chapter 2.2.4.1 if not stated otherwise. 
2.2.4 mRNA isolation and expression analysis 
2.2.4.1 RNA isolation 
2.2.4.1.1 RNA isolation from tissue using TRIzol reagent
50-100mg of frozen human liver samples was homogenized in 1mL TRIzol® reagent using 
an Ultra-Turrax T25 and stored on ice for 15min before removal of cell debris by 
centrifugation (10min, 4°C, 12000xg). The room temperature adjusted supernatant was 
vigorously mixed with 200µL chloroform for 15s, incubated at room temperature for 2min 
and spun down (15min, 12000xg, 4°C) to reach phase separation. The topmost phase, 
containing RNA, was transferred to a fresh tube and mixed with 500µL of isopropanol. After 
10min of incubation, the precipitated RNA was collected by centrifugation (10min, 12000xg, 
4°C). The RNA pellet was washed twice with 75% ethanol (centrifugation at 10000xg and 
4°C for 5min), dried at room temperature and resolved in 100-300µL RNase free water. 
RNA was stored at -80°C until further processing.  
2.2.4.1.2 RNA isolation from cell cultures using an RNeasy Kit
To isolate RNA from HCC cell lines, they were allowed to attach to 6well cell culture plates 
using growth medium. After starvation over night, starvation medium was replaced and 
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5ng/mL TGF- was added 0h, 2h or 24h before collecting the samples. RNA was isolated 
using the RNeasy Kit from Qiagen according to the manufacturer’s protocol. Briefly, adherent 
cell layers were washed with HBSS, collected in RLT lysis buffer supplemented with 1% 
-mercaptoethanol and stored at -80°C until further processing. The lysate was mixed with 
the same volume of 70% ethanol and loaded to an RNeasy spin column, followed by a 30s 
centrifugation step at 13000 rpm. Subsequently, the column was washed once with 700µL 
RW1 and twice with 500µL RPE buffer, including a centrifugation step (see above) between 
each washing step. 40µL of RNAse free water was added to the column and RNA was 
collected by centrifugation into a fresh tube. The RNA was stored at -80°C until further 
processing. 
2.2.4.2 RNA gel electrophoresis 
For the determination of RNA concentration and quality, 2µL of the RNA solution was loaded 
to a NanoQuant plate and analyzed in a microplate reader. Molten 1% agarose in RNase 
free 1xMOPS buffer was poured to a gel casting system with a well comb and was allowed 
to polymerize for 30min. 200ng RNA was mixed with RNA loading buffer and incubated at 
68°C for 10min. These samples were loaded onto the gel and separated in 1xMOPS buffer 
by applying 7mV/(cm electrode distance) for 1h. Ethidium bromide stained RNA was 
visualized with a UV transilluminator system. Visible 28S and 18S ribosomal RNA (rRNA) 
bands, with the last one about half as intense as the former, indicated a good RNA integrity. 
cDNA was only used if a high-quality and similar RNA integrity and no DNA contamination 
was ensured.  
2.2.4.3 Reverse transcription 
Reverse transcription (RT) of RNA to cDNA was performed using the Omnitect Reverse 
Transcription Kit (Qiagen). To disintegrate possible DNA contaminations, 1µg RNA in 12µL 
RNase free water and 2µL gDNA wipe out buffer was incubated at 42°C for 2min using a 
PCR thermal cycler. After the addition of 6µL of a master mix comprising 5x buffer (with 
dNTPs and Mg2+), primer and reverse transcriptase, the RT reaction was performed at 42°C 
for 1h before heat inactivating the enzyme (5min, 95°C). An efficient and equal RT reaction 
was ensured by detection of 18S rRNA using conventional PCR technology. Afterwards, 
Real time PCR was used for comparative expression analysis of various genes (see below).  
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2.2.4.4 Conventional PCR 
To amplify parts of the 18S rRNA sequence, one PCR reaction comprised 2ng cDNA, 1µL of 
a 10µM forward/reverse primer (1:1) mix (Table 2.3, page 29), 0.4µL of a 10mM dNTP 
solution, 0.5U FastStart Taq DNA polymerase, 2µL 10xBuffer with MgCl2.and was filled up 
with double distilled water to 20µL. In a PCR thermocycler, the sample was first incubated at 
95°C for 3min, followed by 15cycles of 30s at 95°C (denaturation), 30s at 60°C 
(annealing) and 1min at 72°C (elongation). After a final incubation step of 5min at 72°C, the 
samples and a DNA marker of known size were mixed with DNA loading buffer and loaded to 
a gel (1% agarose in 1xTAE buffer and 2µL/100mL ethidium bromide), which was placed in 
an agarose gel electrophoresis system filled with 1xTAE buffer. DNA separation by size was 
accomplished by applying 5-10V/(cm electrode distance) for 45-60min. The ethidium 
bromide stained DNA was detected using a UV transilluminator. Equal transcription efficiency 
for different samples was assumed if the detected signal intensities of the amplified 18S 
rRNA cDNA were comparable. 
2.2.4.5 TaqMan and SYBR Green real time PCR analysis 
Expression levels of different TGF- signaling related genes were examined using TaqMan® 
or SYBR® Green real time PCR analysis. 
2.2.4.5.1 TaqMan Real Time PCR
Aqueous 1ng/µL cDNA solutions were used for the detection of mRNA levels of various 
genes, whereas lower cDNA concentrations (5pg/µL) were applied for analysis of 18S rRNA 
expression. A TaqMan master mix of an adequate volume for all samples (Table 2.5) was 
prepared and 18 µL thereof was transferred to a suitable real time PCR plate. After addition 
of 2µL cDNA or a negative control, the Real time PCR plate was sealed with a clear 
adhesive foil and centrifuged for 10s at 1000rpm.  
TaqMan master mix SYBR Green Master mix 
Component 
Volume for 
one 20µL 
reaction 
Component 
Volume for 
one 20µL 
reaction 
TaqMan probe 1µL  Forward primer (5µM) 0.4µL  
2xTaqMan Master Mix 10µL  Reverse primer (5µM) 0.4µL  
ddH2O 7µL  2xSYBR® Green Master Mix 10µL 
   ddH2O 7.2µL  
Table 2.5 Composition of master mixes for TaqMan and SYBR Green real time PCR     
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The gene specific TaqMan probes used for this study are listed in Table 2.2 (page 28). Using 
an AbiPrism7000 real time PCR cycler, the PCR conditions were as follows: 10min at 95°C 
(activation of DNA polymerase) and 40cycles of 15s at 95°C (denaturation) and 1min at 
60°C (annealing and elongation). Each sample was analyzed in triplicates and evaluated as 
described below (chapter 2.2.4.5.3).  
2.2.4.5.2 SYBR® Green PCR analysis
In general, the experimental setup for SYBR Green real time PCR analysis was the same as 
for TaqMan Real time PCR analysis (see above). One exception was the use of a SYBR 
Green (Table 2.5, right) instead of the TaqMan master mix. The used primer pairs for specific 
cDNA detection are listed in Table 2.3 (page 29). The PCR conditions were as described in 
the previous chapter. To exclude possible unwished signals of primer dimers or unspecific 
primer binding, a dissociation curve between 60°C and 90°C was included at the end of 
each experiment. Samples were tested in triplicates and evaluated as described below. 
2.2.4.5.3 Evaluation of real time PCR results
The fluorescence signal of TaqMan dyes or DNA intercalated SYBR Green was detected 
after each elongation step. The threshold for collection of Ct values was set within the linear 
rise of the curve. Each sample was measured in triplicates. The data were analyzed 
according to the Ct method: 
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18S rRNA was identified as suitable reference gene by comparison of its Ct values in all cell 
lines: The mean Ct values (of 3-4 experiments) were calculated for each cell line and varied 
between 19.6 and 20.2 with a standard error below 0.36 in all cases. TGF- treatment did not 
alter 18S rRNA values within one cell line, as seen in variations of the Ct values below 
0.4cycles.   
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2.2.5 SDS-PAGE gel electrophoresis and immunoblot analysis 
2.2.5.1 Protein lysates of cultured cells 
HCC cell lines were allowed to attach to 9.6cm² cell culture wells before replacing growth 
medium with starvation medium. The next day, cells were treated with 5ng/mL TGF- 0h, 
1h, 3h, 8h, 24h or 48h before collecting the cells. For a comparison of basal protein levels, 
cells were incubated in starvation medium for 24h. the end of an experiment, cells were 
washed with HBSS and disrupted in ice-cold RIPA buffer containing phosphatase and 
protease inhibitors. Cells were stored at -80°C until further processing and for a better cell 
disruption. Cell lysates were scraped with a rubber policeman, transferred to a collection tube 
and spun down to remove cell debris (15min, 13000rpm, 4°C). After determination of 
protein concentrations, proteins were separated by an SDS-PAGE gel electrophoresis and 
immobilized on a membrane for immunodetection of protein levels (see below).. 
2.2.5.2 Determination of protein concentration 
Protein concentrations were determined using a BC protein assay, which is based on the 
Lowry assay. The principle of this assay is the reaction of amino acids with an alkaline 
copper tartrate and Folin reagent, which results in a reduction of Folin to a blue product. 2µL 
of protein samples or of a BSA (bovine serum albumin) standard curve with known 
concentrations (0-10mg/mL) were transferred to a microtiter plate and supplemented with 
20µL of a mix of 1000µL solution A and 20µL of solution S (alkaline copper tartrate). 200µL 
solution B (Folin reagent) was added and after 10-15min, the absorbance was detected at 
690nm using a microplate reader. Each sample was measured in triplicates and unknown 
protein concentrations were calculated using the BSA standard curve.  
2.2.5.3 Sample preparation for immunoblot 
For denaturation of disulfide bonds, a mixture of 20-30µg protein lysate and 6µL reducing 
protein loading buffer was incubated at 95°C for 10min and stored on ice. Within the next 
hour, protein samples were loaded to an SDS-PAGE gel for protein separation (see below).  
2.2.5.4 Preparation of SDS-polyacrylamide gels and gel electrophoresis 
Protein separation by size was achieved performing an SDS-PAGE (sodium dodecyl sulfate-
polyacrylamide gel electrophoresis). For this, 1.5mm thick Bis-acrylamide (12%) gels were 
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poured in gel casting systems from Bio-Rad: The separating gel (Table 2.6, see below) was 
freshly prepared and immediately casted between two glass plates, leaving enough space for 
the stacking gel. This separating phase was covered with isopropanol to ensure a sharp and 
linear edge. The gel was allowed to polymerase for 30min before isopropanol was removed. 
The space between the two glass plates was filled up with the freshly prepared stacking gel 
(Table 2.6) and a comb with 15 slots was added. After polymerization for 45-60min, the gels 
were installed in an electrophoresis module. The space between two gels as and the running 
chamber itself was filled with 1x Lämmli buffer (page 29). The comb was carefully removed 
and the wells were washed thoroughly before a protein marker of known sizes and samples 
were loaded to the gels. Protein alignment in the collection phase was allowed at 40 V. Once 
the running front reached the separating gel, the voltage was increased to 80-110 V.  
Separating gel, 12 % Stacking gel 
Acrylamide 2.6 mL  Acrylamide 0.3 mL 
1.5 M Tris-HCl, pH 8.8 1.6 mL  1M Tris-HCl pH 6.8 0.5 mL 
ddH2O 2.2 mL  ddH2O 1.1 µL 
SDS (10%) 66.7 µL  SDS (10%) 19.1 µL 
TEMED 6.0 µL  TEMED 3.4 µL 
APS (10%) 40 µL  APS (10%) 22.9 µL 
Table 2.6 Composition of separating and stacking gel for SDS-PAGE gel electrophoresis 
2.2.5.5 Western transfer 
Immunoblot (Western blot) analysis was used to immobilize proteins on a nitrocellulose 
membrane (0.45micron, Pierce, Rockford, IL). A sandwich was prepared, with the gel and 
the membrane in the middle, followed by three chromatography papers (3MM Chr, 
Whatmann, Maidstone, England), and blotting pads on both sides. To build this Western 
sandwich, the different layers were wetted in 0.5xTowbin transfer buffer (page 30) and 
bubbles between the layers were carefully removed to ensure accurate protein transfer. The 
transfer was performed in a blotting module filled with 0.5xTowbin transfer buffer, with the 
membrane closer to the anode and the gel closer to the cathode. For protein transfer, 
250-300mA per membrane was applied over a time period of 4h.   
2.2.5.6 Immunodetection of proteins 
Membrane bound proteins were temporarily stained with Ponceau S Red solution to ensure 
equal loading and satisfying blot quality and to identify possible transfer mistakes. The 
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membrane was washed in TBST (page 30) and blocked with 5% non fat dried milk in TBST 
for 1h at room temperature. After washing with TBST, the membrane was incubated with a 
protein specific (first) antibody overnight at 4°C and was then washed again (3x 5min) to 
remove unbound antibodies. The membrane was incubated with a species specific (second) 
antibody conjugated to a horseradish peroxidase (HRP). Antibodies are listed in Table 2.4 
(page 31). After 1-2h at room temperature, the membrane was washed three times in TBST. 
All washing and incubation steps were conducted under agitation on a shaker. Horseradish 
peroxidase activity was detected by wetting the membrane with ECL solution and capturing 
the resulting chemiluminescence using a luminescent image analyzer.   
For further analysis with the same membrane, the antibodies associated to the membrane 
were detached. For this, the membrane was washed 2min in TBST, 2min in distilled water 
and subsequently incubated in aqueous 0.2N sodium hydroxide solution for 5min. After 
washing with water and TBST, the membrane could be used again.  
2.2.6 Statistical Analysis 
Cell line data are presented as the mean ± the standard error (SE) of at least three 
independent experiments, if not stated otherwise. In some cases, statistically significant 
differences were identified by Student’s t-test. Correlation analysis was performed by 
calculating the Pearson correlation coefficient r.  
For human HCC patient samples, a chi-square (2) analysis was performed to identify 
possible associations between different Smad7 expression levels and clinicopathological 
characteristics. A 2x2 table was used and patients were grouped as: Smad7 overexpression 
or no Smad7 overexpression (unchanged or reduced mRNA levels).  
For all tests, significant levels are indicated as *p < 0.05, **p < 0.01 and ***p < 0.001. 
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3 RESULTS
3.1 Heterogeneous cytostatic effects of TGF- in HCC cell lines 
TGF- exerts anti-proliferative and pro-apoptotic effects on hepatocytes (chapter 1.2). 
Cancer cells frequently develop resistance to these effects. Therefore, the behavior of nine 
different HCC (HCC-M, HCC-T, HepG2, Hep3B, HuH7, FLC-4, PLC/PRF/5, HLE and HLF) 
and hepatoblastoma cell line HuH6 regarding proliferation and survival upon TGF-
treatment was investigated.  
3.1.1 Divergent effects of TGF- on proliferation in different HCC cell lines 
Liver cancer cell lines were cultured at a low density and treated with TGF- for 2 or 6 days. 
Upon TGF- stimulation, the different cell lines showed various responses ranging from 
induction of growth arrest to stimulation of proliferation (Figure 3.1, right side).  
Figure 3.1 Ambiguous effects of TGF- on proliferation in HCC cell lines.  (Left) HCC cell lines were 
either treated with 5 ng/mL TGF- or left untreated for indicated time points. Changes in c-Myc and 
p21 expression were detected using immunoblot analysis with GAPDH as a loading control. In line 
with the late proliferative response in HCC-T cells (right diagram), changes in c-Myc levels were 
also delayed (after 72h instead of 8h). Results were confirmed with a second independent 
experiment. (Right) After TGF- treatment for 0 (grey line), 2 (white bars) or 6 days (black bars), 
cell proliferation was evaluated by MTT assays. Treated samples were normalized to control 
samples of the same cell line. Significant differences are indicated as *p < 0.05, **p < 0.01 and 
***p < 0.001 (Student’s t-test). Results are shown as means +SE.  
Overall, proliferation rates of four cell lines (HCC-M, HLE, HLF and FLC-4) remained 
unaltered following TGF- treatment. The cytokine marginally reduced proliferation in HLF 
cells after 6 days of TGF- treatment. In other cells, TGF- interfered with proliferation, 
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interestingly, with different sensitivities. The strongest effects of TGF- were observed in 
PLC/PRF/5, Hep3B and HuH7 cells, as seen by reduction of cell viability to 60% after 2 days 
and to 11-25% after 6 days. TGF- triggered a delayed anti-proliferative response in HepG2 
and HuH6 cells with no or minor growth inhibition after 48h, but a pronounced induction of 
growth arrest after 6 days (35% and 26% viable cells). In contrast to all other cell lines 
analyzed, HCC-T cells significantly (p<0.01) increased cell division to 124% upon long term 
TGF- treatment (6 days).  
The protein p21 is involved in cell cycle control and is described as an indicator of growth 
arrest. In contrast, c-Myc is able to encourage proliferation (Chapter 1.2). Immunoblot 
(Western blot) analysis (Figure 3.1, left) revealed a strong TGF- dependent increase of p21  
and decrease of c-Myc levels in cell lines which were sensitive to TGF- induced growth 
arrest: Hep3B, HuH7, PLC/PRF/5, HepG2 and, with a lower intensity, HuH6 cells. TGF-
also moderately enhanced p21 levels in HCC-M, HCC-T and FLC-4 cells, which were 
insensitive to TGF- mediated inhibition of proliferation. c-Myc levels, however, were not 
affected by TGF- in those cell lines. In line with the pro-proliferative effect of TGF- in 
HCC-T cells, TGF- increased c-Myc protein levels after 72 h.  
3.1.2 Varying sensitivities regarding TGF- induced cell death in HCC cell 
lines 
TGF- is a well recognized mediator of cell death, but this signaling branch is often disrupted 
in cancer (chapter 1.2 and 1.4.2). To evaluate effects of TGF- on cell death, HCC cell lines 
were treated with TGF- for 3 days and LDH release was quantified. LDH is a prominent and 
very stable enzyme in the liver and therefore is a good tool to evaluate cell damage.  
Cell death was calculated as ratio of released LDH of dying cells to total amounts of viable 
and dying cells. Untreated samples were defined as zero to achieve a better comparability 
between the cell lines. Figure 3.2 shows that four cell lines, HCC-T, HLE, HLF and FLC-4, 
were resistant against TGF- induced cell death, whereas minor inductions of cell death 
were detected in HepG2 and HuH6 cells (increase of 7.0% and 4.5%). In contrast, TGF-
strongly enhanced death rates of Hep3B, HuH7 and PLC/PRF/5 cells to 29.8%, 36.5% and 
19.5%, respectively. In those three cell lines, the high sensitivity towards TGF- caused cell 
death was mirrored in cleavage and thereby activation of caspase 3 (a member of the 
apoptotic cascade) and in the proteolytic degradation of caspase target PARP (immunoblot 
in Figure 3.2). TGF- did not alter caspase 3 and PARP in all other cell lines. Interestingly, 
HCC-M cells responded to TGF- with a reduction of basal cell death rates.  
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 Figure 3.2 TGF- induces cell death in Hep3B, HuH7 and PLC/PRF/5 cells. (Left) Immunoblot analysis of 
PARP and caspase 3 cleavage using GAPDH expression as a loading control was conducted after 
48 h TGF- treatment. Untreated samples were used as controls. In the case of HuH7 cells, the 
control sample was treated with TGF- for 3 h. The blots show representative results of at least two 
independent tests. (Right) Cell death induced by 5ng/mL TGF- over 72h (filled bars) was 
quantified by detecting the ratio of LDH release to total amount of LDH. Untreated samples were 
defined as 0 (grey line) and treated samples are shown as filled columns. The results are shown as 
mean +/- SE of at least three independent experiments. Significant differences are indicated as 
*p < 0.05, **p < 0.01 and ***p < 0.001 (Student’s t-test). 
In summary, results shown in chapter 3.1.1 and 3.1.2 identify two different groups, 
showing either resistance or sensitivity towards TGF- induced cytostasis. Hep3B, 
HuH7 and PLC/PRF/5 cells underwent strong induction of cell death, accompanied by 
growth arrest, while HepG2 and HuH6 cells mainly reacted with proliferation inhibition. 
All other cell lines showed resistance against the described effects, with HCC-T even 
showing increased cell division and HCC-M a reduced basal cell death upon TGF-
treatment.    
3.2 Endogenous and TGF- dependent changes in expression of 
canonical TGF- signaling components in HCC cell lines 
Mature TGF- dimers mainly signal through a heterotetrameric receptor complex composed 
of TGF- receptor II and I, which transfer the signal into the cell by phosphorylation of 
receptor (R)-Smads 2 and 3. Activated R-Smads then form a transcription factor complex 
with Smad4. This signaling cascade is effectively blocked by Smad7 (chapter 1.1.1 and 
1.1.2). The experiments described above revealed resistance against cytostatic effects of 
TGF- in many HCC cell lines. Hence, a detailed analysis of canonical TGF- signaling 
components was performed to delineate the underlying mechanism of these findings. 
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3.2.1 Basal expression analysis of TGF- signaling components 
A comparative analysis of endogenous expression levels of TGF-β signaling components 
was performed to investigate the impact on observed cytostatic effects of TGF-β in the 
different cell lines.  
3.2.1.1 Varying endogenous Smad7 levels in HCC cell lines correlate with TGF-1 
expression 
Figure 3.3 Smad7 mRNA levels correlate with TGF-1 expression in HCC cell lines. Relative Smad7 (left) 
and TGF-1 (middle) expression levels were detected using TaqMan real time PCR. Expression of 
18S rRNA was used as a reference gene. The results are pictured as mean +SE of at least three 
independent experiments. A strong correlation (right) of Smad7 and TGF-1 expression was 
identified by calculating the Pearson coefficient (r = 0.87; p = 0.0011).   
The quantity of the TGF- cytokine and its inhibitory opponent Smad7 are two major factors 
which decide the outcome of activated TGF- signaling. Real time PCR analysis of Smad7 
revealed a strong variation in relative mRNA levels in the different HCC cell lines. It ranged 
from 1fold in HCC-M cells, rising over PLC/PRF/5, HCC-T, HepG2 (2.1fold), Hep3B 
(3.7fold), HuH7, HLE and HLF cells to 4.6fold and to 9.7 and 11.0fold in FLC-4 cells and in 
the hepatoblastoma cell line HuH6, respectively (Figure 3.3, left diagram). TGF-1 is the 
predominant isoform in the liver. Similar to Smad7, it was heterogeneously expressed in the 
different cell lines, being lowest in HuH7 cells and highest in the cell line FLC-4 with 9.8fold 
increased levels when normalized to HuH7 cells (Figure 3.3, middle). Here, relative TGF-1 
expression in HuH7, HCC-T, PLC/PRF/5, HepG2 and HCC-M cells varied between 1-1.34 
fold, whereas medium levels of 2.6 to 3.9fold were identified for HLE, Hep3B and HLF cells. 
HuH6 and FLC-4 featured highest TGF-1 mRNA levels (5.7 and 9.8fold). Interestingly, 
TGF-1 expression significantly (r = 0.87, p = 0.0011) correlated with Smad7 mRNA levels, 
as identified by calculating the Pearson correlation coefficient (Figure 3.3, right).  
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3.2.1.2 TGF- receptor I, Smad2 and Smad4, but not TGF- receptor II and Smad3 are 
overall evenly expressed 
Figure 3.4 shows basal mRNA expression levels of the TGF- receptor I (TRI) and II 
(TRII). Real time PCR analysis identified HCC-M as the cell line with highest TRI mRNA 
levels, which were 5.6fold increased in comparison to HLE cells (Figure 3.4, left). Expression 
levels among the other cell lines were relatively stable, ranging from 1fold in HLE to 2.4fold 
in HuH7 cells, with FLC-4 as an outlier (2.9fold). In contrast, TRII mRNA levels (middle 
diagram), normalized to its expression in HCC-M cells, varied strongly in the different cell 
lines. TRII expression was increased in HLF, FLC-4, HuH6, HLE (1.6-3.3fold) and Hep3B 
and HuH7 cells (about 5 fold) when compared to HCC-M and HCC-T cells (1-1.2fold). 
Figure 3.4 Expression of TGF- Receptor 1 (TRI) is relatively stable while receptor 2 (TRII) levels are 
heterogeneous in HCC cell lines. Expression levels of TRI (left) and TRII (middle) were 
detected using TaqMan real time PCR with 18S rRNA expression as a reference. Shown 
experiments represent the mean + SE of three independent experiments.  In the table, cell lines 
marked as black showed TGF- induced cell death and growth inhibition whereas cells highlighted 
as grey mainly reacted with the latter one. In a second calculation, TRII expression was 
normalized to TRI mRNA of the cell line to identify the TRII/TRI ratio (right).  
However, highest TRII amounts were detected in PLC/PRF/5 and HepG2 cells with 7.0 and 
8.6 times elevated levels, respectively. Interestingly, except for HCC-M and HCC-T cells, 
TRII expressions were elevated in cell lines with low Smad7 mRNA levels (compare to 
Figure 3.3 or table in Figure 3.4). After exclusion of HCC-M and HCC-T, a significant 
negative correlation was observed between Smad7 and TRII mRNA levels (r = -0.72, 
p = 0.044, not shown). Further, TRII expression was highest in cells responsive to TGF-
mediated cytostasis (table in Figure 3.4 or Figure 3.1 and 3.2), namely PLC/PRF/5, HepG2, 
Hep3B and HuH7. Only HuH6 cells expressed lower TRII levels than HLE, the cell line of 
the non-responders with the highest expression. Noteworthy, TRII expression was higher 
than TRI in all but HCC-M cells (Figure 3.4, right diagram). 
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Figure 3.5 Smad2 and Smad4 are equally expressed, while Smad3 levels strongly vary in different HCC 
cell lines. Relative Smad3 (left), Smad2 (middle) and Smad4 (right) mRNA and protein levels were 
detected using either real time PCR with 18S rRNA as a reference gene or Western blot analysis 
with GAPDH as a loading control. Real time PCR results are presented as mean +/- SE of at least 
three independent results. Western Blot results show one representative of two independent 
experiments.  
Upon activation of the TGF- receptor complex, receptor Smads are phosphorylated and 
form heteromeric transcription factor complexes with Smad4. Therefore, the impact of basal 
R-Smad2 and 3 and common-mediator Smad4 expression on different sensitivities towards 
TGF- induced apoptosis and growth arrest (Chapter 3.1) was evaluated. Immunoblot as 
well as real time PCR analysis revealed rather stable expression levels of Smad2 and 
Smad4 between the cell lines (Figure 3.5). Smad2 mRNA levels (middle diagram) were 
highest in HuH6 (2.6fold increase) when compared to HepG2 cells, whereas Smad4 
expression levels ranged from 1fold in HCC-M to 2.2fold increase in FLC-4 cells. In contrast 
to Smad2 and Smad4, heterogeneous amounts of Smad3 mRNA and protein were detected 
in the different cell lines (Figure 3.5, left diagram). No correlation to the observed cytostatic 
behavior was detectable. Relative to HCC-M cells, Smad3 mRNA levels were 1.8-7.2times 
increased in HCC-T, HepG2, HuH7, FLC-4, HuH6, PLC/PRF/5 and Hep3B cells, but the 
highest expressions were detected in HLE and HLF cells (14.0 and 19.5fold). Altogether, 
those findings were confirmed by immunoblot analysis, which identified the strongest Smad3 
signal intensities for Hep3B, HLF and HLE cells and the lowest intensities in HCC-M cells.    
3.2.2 Effects of TGF- on expression of its canonical signaling components 
Regulation of TGF- signaling occurs via different TGF- dependent mechanisms. After 
analyzing basal levels of TGF- signaling components, the impact of TGF-1 stimulation on 
their expression was the next focus of investigation. 
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3.2.2.1 TGF- induces its type II but not type I receptor in cells sensitive to TGF-
induced cytostasis 
Effects of TGF- on the expression of its receptors were investigated using real time PCR 
analysis. HCC cell lines were treated with TGF- for 24 h, and TRI and TRII mRNA levels 
were compared to untreated control samples.  
Figure 3.6 TGF- modifies TRI but not TRII expression in HCC cell lines. Liver cancer cell lines were 
treated with (filled bars) or without (grey line) 5 ng/mL TGF- for 24 h. Real time PCR detecting 
TRII (left) and TRI (middle) mRNA levels was performed using 18S rRNA as a reference gene. In 
the table (right), cell lines sensitive to TGF- induced growth arrest but not cell death are marked as 
grey, whereas black represents cells reacting with both. Real time PCR experiments are presented 
as mean +/- SE of at least three independent experiments. Significant differences are labeled as 
*p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t-test).  
TGF- stimulation resulted in minor inhibition of TGF- receptor II expression in all but 
HCC-M, HCC-T and HepG2 cells. This effect was strongest in PLC/PRF/5 and Hep3B cells 
with a significant repression to 0.6fold (p < 0.001; Figure 3.6, left). In contrast, TGF-
significantly induced TRI expression by a factor of 3.3-3.5 in HCC cell lines (Hep3B, HuH7 
and PLC/PRF/5) which were sensitive to TGF- induced cell death (Figure 3.6, right diagram 
and table). Additionally, a TGF- dependent 1.7-1.9fold increase of TRI mRNA levels was 
observed in HLE and HepG2 cells. In all other cell lines, TGF- did not alter TRII 
expression, including HuH6 cells, which were responsive to TGF- induced growth arrest.    
3.2.2.2 TGF- alters Smad3, but not Smad2 or Smad4 expression 
Smad2, Smad3 and Smad4 are the main signaling mediators of TGF- inside the cells and 
their expressions after stimulation with TGF- in comparison to untreated controls were 
therefore carefully analyzed for the different liver cancer cell lines. As demonstrated in Figure 
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3.7 (left and middle), Smad2 and Smad4 mRNA were not altered decisively upon 24h TGF-
treatment. The cytokine slightly inhibited Smad2 expression in HCC-M cells (0.7fold, 
p < 0.05), whereas a marginal upregulation was found in HepG2 and HuH6 (1.3fold, p < 0.01 
and < 0.05) cells. Similarly, Smad4 levels varied between 0.8 and 1.1fold expression 
regulations by TGF-, with a negligible but significant induction in HepG2 and Hep3B cells. 
The finding that external TGF- stimulation did not influence Smad2 and Smad4 levels, was 
confirmed on the protein level by performing immunoblot analysis after 24h of TGF-
treatment (Figure 3.8).   
Figure 3.7 TGF- induces Smad3, but not Smad2 and Smad4 expression in HCC cell lines sensitive to 
TGF- induced cytostasis. HCC cell lines were treated with (filled bars) or without (grey line) 
5 ng/mL TGF- for 24 h. Expression levels of Smad2 (left), Smad4 (middle) and Smad3 (right)  
were detected using real time PCR with 18S rRNA expression as a reference gene. In the table, 
cell lines marked as black showed TGF- induced cell death and growth inhibition whereas cells 
marked as grey mainly reacted with the latter one. Results are shown as mean +SE from at least 
two independent experiments. Significances are indicated as *p < 0.05, **p < 0.01, ***p < 0.001 
(Student’s t-test). 
In contrast, TGF- considerably enhanced Smad3 mRNA levels (Figure 3.7, right diagram) in 
cell lines with a cytostatic TGF- response (compare to table in Figure 3.7 or chapter 3.1). It 
resulted in a significant 2.0-2.2 fold increase of Smad3 expression in HepG2 and HuH6 cells 
(p < 0.05), which showed a TGF- mediated inhibition of proliferation. This effect was even 
more pronounced in cell lines which additionally died upon TGF- treatment. Here, TGF-
enhanced Smad3 expression by the factor 2.9-4.5 in PLC/PRF/5, Hep3B and HuH7 cells. 
Interestingly, no TGF- dependent changes or a rather faint inhibition of Smad3 expression 
was observed in cell lines resistant to TGF- induced cytostasis, such as HCC-M, HCC-T, 
HLE, HLF and FLC-4 cells. Most significant repression was found in HLE and HLF cells with 
about 0.75 fold expression when compared to untreated samples.  
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Figure 3.8 TGF- alters Smad3 but not Smad2 and Smad4 protein levels. Smad2, Smad3 and Smad4 
protein expression in control samples and cells treated with TGF- for 24 h was evaluated by 
immunoblot analysis using GAPDH as a loading control. * and ** indicate which GAPDH belongs to 
Smad2 and Smad3 or Smad4, respectively. The results show one representative of two 
independent experiments. 
These findings were confirmed by immunoblot analysis (Figure 3.8), revealing a distinct 
increase of Smad3 protein levels in PLC/PRF/5, HepG2, Hep3B, HuH7 and HuH6 cells, 
while those in HCC-M, HCC-T and FLC-4 cells remained stable upon TGF- treatment for 
24h. Furthermore, a minor TGF- mediated decrease of Smad3 protein amounts was in line 
with slightly reduced Smad3 expression in HLE and HLF cells (compare Figure 3.8 to 3.7).  
3.2.2.3 TGF- induced Smad7 expression is highest in cell lines with low basal 
Smad7 expression 
Smad7 is a potent inhibitor of canonical TGF- signaling, and its expression is induced by 
TGF- in a negative feedback loop. Given that Smad7 in turn may exert significant influence 
on TGF- outcome, TGF- induced Smad7 expression was investigated.  
Real time PCR analysis identified different Smad7 inductions upon 2h of TGF-
administration in various cell lines (Figure 3.9, upper left). Interestingly, when excluding 
HCC-M and HCC-T cells, basal (Figure 3.3 or gradient in Figure 3.9) and induced Smad7 
mRNA levels showed a strongly negative correlation to each other (Pearson coefficient 
r = -0.74, p = 0.034; Figure 3.9 lower left). This implies that Smad7 induction is higher in cell 
lines with low endogenous expression and the other way around. HCC-M and HCC-T cells 
differed from this behavior, as seen in low basal Smad7 levels but almost no induction by 
TGF- (<1.5 fold; Figure 3.9, upper left). With that, they were in the same range as FLC-4, 
HLF and HuH6 cell, which had high basal Smad7 levels and a TGF- dependent 1.2-1.8fold 
induction. In PLC/PRF/5, HepG2 or Hep3B cells with rather low endogenous Smad7 
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transcription, TGF- strongly elevated Smad7 expression by a factor of 9.4, 6.6 and 5.1, 
respectively. Consistently, TGF- moderately increased Smad7 expression to 3.2 and 
2.6fold in HuH7 and HLE cells, respectively; two cell lines with medium basal Smad7 levels. 
Figure 3.9 TGF- induced expression of target gene Smad7 is lowest in cell lines with high basal 
expression. ( Upper left diagram) HCC-T cells were either treated with 5ng/mL TGF- (filled bars) 
or left untreated (grey line) for 2h. Relative Smad7 expression levels were evaluated using real 
time PCR with 18S rRNA as a reference gene. (Upper right diagram) HCC cells were transfected 
with a Smad7 promoter reporter assay, which was evaluated after 6h of stimulation with or without 
5ng/mL TGF-. TGF- treated samples (filled bars) were normalized to the corresponding 
untreated control (grey line). Results show the mean +SE of at least three independent 
experiments. (Right table) Cell lines with the strongest Smad3/Smad4 transcriptional activity (Figure 
3.11, page 58) are marked as black. The gradient stands for increasing basal Smad7 expression. 
(Lower diagrams) Correlation analysis was performed by calculation of the Pearson coefficient r
between relative TGF- induced Smad7 mRNA levels and basal Smad7 expression (left) as well as 
relative Smad7 promoter activity (right). In the left diagram, HCC-M and HCC-T cells, which were 
excluded from the analysis, are shown as open squares.  
Next to analysis of Smad7 mRNA levels, a reporter assay was performed, using the firefly 
luciferase gene under control of parts of the human Smad7 promoter (Figure 3.9, upper right 
diagram). This promoter fragment is sufficient for TGF- induced activity [37]. Data were 
acquired in collaboration with Jasmin Fabian from the same group. Reporter assay analysis 
validated the results of real time PCR. 6 h after TGF- stimulation, there was no elevation of 
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promoter activity in HCC-M and HCC-T cells, but a 2.8-4.1 fold increase in Hep3B, 
PLC/PRF/5, HuH7 and HepG2 cells when compared to untreated controls. In all other cell 
lines, TGF- treatment resulted in only minor inductions (1.3-1.8 fold). Correlation analysis 
confirmed a strong similarity between the results of Smad7 mRNA and promoter activity 
analysis (Pearson coefficient r = 0.77, p < 0.01; Figure 3.9, lower right). Furthermore, TGF-
most efficiently induced Smad7 transcription in cell lines with a high induced Smad3/Smad4 
transcriptional activity (CAGA activation; table in Figure 3.9 or Figure 3.11, page 58). 
In summary, the results presented in chapter 3.2 demonstrate that Smad7 expression 
strongly correlated with TGF-1 mRNA levels. Interestingly, except for HCC-M and 
HCC-T, TGF-’s ability to induce Smad7 expression was reduced with rising 
endogenous Smad7 transcription. Overall, TRI expression was rather stable between 
the various cell lines and, in general, lower than TRII. The latter was predominantly 
expressed in cell lines sensitive to TGF- induced cytostasis and expression 
remained unaltered following TGF- treatment. Interestingly, TGF-1 enhanced TRI 
mRNA levels in exactly those cell lines. Finally, Smad2 and Smad4 expression was 
stable, both endogenously and after TGF- treatment. In contrast, Smad3 was 
expressed heterogeneously in different HCC cell lines, but did not correlate with 
TGF- sensitivity. However, Smad3 expression was induced by TGF- only in cell lines 
which were sensitive to TGF- mediated cytostasis.  
3.3  Effects of TGF- on Smad2 and Smad3 activity in HCC cell lines 
Modified levels of TGF- signaling components do not necessarily reflect changes in signal 
transduction intensity. Consequently, an analysis of R-Smad activation and functionality was 
conducted.   
3.3.1 TGF- enhances Smad2 and Smad3 activity in HCC cell lines  
Intracellular TGF- signaling is implemented by receptor mediated phosphorylation and 
thereby activation of receptor Smads, mainly Smad2 and Smad3 (chapter 1.1.2). Hence, an 
analysis of the intensity and duration of R-Smad activation was important for a detailed 
delineation of TGF- signaling in HCC cell lines.         
Immunoblot analysis suggests a strong variation in durations of TGF- dependent Smad2 
activation in the different cell lines, ranging from 1h to 48h (Figure 3.10, left). By trend, cell 
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lines with high Smad7 expression showed a transient activation of Smad2 for 1h, which was 
clearly reduced after 3h, as seen in HLE, HLF, FLC-4 and HuH6 cells. In contrast, TGF-
treatment in HCC-M and HCC-T, but also PLC/PRF/5 cells with low Smad7 mRNA levels 
resulted in a prolonged Smad2 activation of up to 48h. HepG2 and Hep3B cells displayed an 
exception, with rather short signaling but low Smad7 expression in HepG2 cells and higher 
Smad7 and longer signaling duration in Hep3B cells. Overall, calculation of the Pearson 
coefficient suggest a negative, but insignificant correlation between the duration of the 
Smad2 activation and Smad7 mRNA levels (r = -0.55, p = 0.102). 
Figure 3.10 TGF- induced activation of Smad2 is heterogeneous in different HCC cell lines but weakly 
correlates with Smad7 expression. (Left) HCC cell lines were treated with 5 ng/mL TGF-  
0, 1, (3), 7, 24 and 48 h before cell lysis. Immunoblot analysis of phosphorylated Smad2 and 
GAPDH as a reference was performed. The immunoblots show one representative example of at 
least two independent experiments. The table characterizes the cell lines regarding cytostatic 
response, with cells showing TGF- induced growth arrest in grey and cell lines additionally 
reacting with cell death in black. The gradient from white to black displays increasing basal Smad7 
expression levels. (Right) Cell lines were transfected with a plasmid carrying a luciferase gene 
under the control of ARE. Smad2 transcriptional activity was detected 9 h after treatment with (filled 
bars) or without (grey line) 5 ng/mL TGF-. Results are presented as the mean +/-SE of three 
independent experiments. 
Activated Smad2 forms a transcription factor complex with Smad4, which then, together with 
DNA binding proteins such as Fast-1, regulates gene expression by binding to an activin 
responsive element (ARE; chapter 1.1.2, page 3). As the formation of this complex and its 
binding to DNA can be affected by many factors, it was indispensable to analyze Smad2 
transcriptional activity after TGF- treatment using an ARE-luciferase reporter assay. TGF-
strongly induced luciferase activity by a factor of 14.8, 32.7 and 102.1 in cytostasis sensitive 
HuH7, PLC/PRF/5 and HepG2 cells, respectively (Figure 3.11, right). HuH6 and Hep3B cells, 
which were responsive to TGF- induced cytostasis, showed similar inducibility in resistant 
HLE and HLF cells (4.1-4.8fold). Despite a clear activation of Smad2, TGF- was unable to 
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markedly induce Smad2 transcriptional activity in HCC-M, HCC-T and FLC-4 cells. However, 
preliminary data using a TRI inhibitor (data not shown) suggest that this pathway is 
endogenously activated in those cell lines, as the inhibitor reduced basal Smad2 
transcriptional activity to 10%. In line with that, basal activity was lowest in cells with the 
highest inducibility by TGF-, namely HepG2 and PLC/PRF/5.  
Figure 3.11 TGF- mediated Smad3 activation is prolonged but does not correlate to Smad3 
transcriptional activity in HCC cell lines. (Left) HCC cell lines were treated with 5ng/mL TGF-
0, 1, 3, 7, 24 and 48h before cell lysis. Afterwards, immunoblot analysis of phosphorylated Smad1 
(upper band) and 3 (lower band) as well as GAPDH as a loading control was performed. The 
immunoblot represents two independent experiments. (Middle) The table characterizes the cell 
lines regarding cytostatic response, with cells showing TGF- induced growth arrest in grey and cell 
lines additionally reacting with cell death in black. The gradient from white to black displays 
increasing basal Smad7 expression levels. (Right) Cell lines were infected with an adenovirus 
encoding a luciferase gene under the control of a CAGA response element. Smad3/Smad4 
transcriptional activity was detected 9h after treatment with (filled bars) or without (grey line) 
5ng/mL TGF-. Results are presented as mean +SE of three independent test.  
Immunoblot analysis shows that TGF- mediated Smad3 phosphorylation did not correlate 
as clearly with basal Smad7 levels as Smad2 activation (Figure 3.11). Except for HepG2, 
HLF and FLC-4 cells, TGF- induced Smad3 activation was prolonged and lasted for up to 
48h. No correlation to the cytostatic TGF- response was observed (Figure 3.11, table). 
Finally, TGF- stimulation resulted in a transient Smad1 activation in all but HCC-M cells, 
which showed considerably prolonged signal duration until at least 48h of TGF- treatment.  
Smad3 activation results in the formation of a transcription factor complex, which regulates 
gene expression by binding to a CAGA element (chapter 1.1.2, page 3). To analyze whether 
TGF- activated Smad3 signaling is interrupted downstream of the R-Smad activation, a 
CAGA-luciferase reporter assay with or without TGF- stimulation for 9 h was performed. 
Although TGF- strongly induced Smad3 phosphorylation, the resulting Smad3/Smad4 
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transcriptional activity was low (1.7-2.8fold) in HuH6, HCC-M and HCC-T in comparison to 
untreated controls (Figure 3.11, right diagram).  A TR1 inhibitor was unable to reduce basal 
Smad3 transcriptional activity as dramatically as in the case of Smad2 (preliminary data, not 
shown), indicating lower endogenous Smad3 activation. FLC-4, HLE, HLF and HepG2 
showed a TGF- dependent 6.8 to 9.7fold increase of basal CAGA-Luc activity. However, 
highest inductions by a factor of 16.9-21.4 were found in Hep3B, PLC/PRF/5 and HuH7 cells. 
These were cell lines with relatively low amounts of TGF- and Smad7 mRNA and with 
sensitivity towards TGF- induced cell death (table in Figure 3.11 and Figure 3.3).    
3.3.2 Induction of Smad3 target genes Bim and PAI-1 by TGF- correlates with 
Smad3/Smad4 transcriptional activity 
The previous results demonstrate that TGF- induced cytostasis correlated with increased 
Smad3 transcriptional activity, which was accompanied by a stronger induction of the TGF-
target gene Smad7. To strengthen these observations, I examined the impact of TGF- on 
further Smad3/Smad4 target genes, Bim and PAI-1. 
Figure 3.12 TGF- induces Smad3/Smad4 target genes Bim and PAI-1 in HCC cell lines with high CAGA 
activity. Real time PCR against Bim (left) and PAI-1 (middle) was performed after stimulation with 
(filled bars) or without (grey line) 5ng/mL TGF- for 24h and 2h, respectively. 18S rRNA was used 
as a reference gene. Data are presented as the mean +SE of three independent experiments. 
(Right) The table demonstrates which cell lines showed a strong TGF- induced Smad3/Smad4 
transcriptional activity (CAGA-Luc assay, Figure 3.11). 
Expression of pro-apoptotic Bim is induced Smad3 dependently during TGF- mediated 
activation of the apoptotic cascade in hepatocytes [71, 234]. Real time PCR experiments 
after 24h of TGF- stimulation (Figure 3.12) revealed an induction of Bim expression in HCC 
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cell lines which were responsive to TGF- caused cell death, namely Hep3B, HuH7 and 
PLC/PRF/5 (3.2, 4.2 and 14.9fold when normalized to untreated controls). TGF- was 
unable to enhance Bim expression in all other cell lines, including HepG2 cells with good 
inducibility of CAGA-Luc activity. In contrast, Bim expression was weakly inhibited by TGF-
to 73% and 81% in HCC-M and HLF (p < 0.05) cells. 
Another Smad3 target gene is plasminogen activator inhibitor-1 (PAI-1). TGF- induces 
PAI-1 expression during EMT in hepatocytes [139, 140]. In the analyzed liver cancer cell 
lines, TGF- strongly enhanced PAI-1 mRNA levels in PLC/PRF/5, Hep3B and HuH7 cells 
(three out of four cell lines with the highest CAGA-Luc activity measured). In comparison to 
untreated control samples, TGF- led to a 5.3, 8.2 and 12.8fold induction of PAI-1 in Hep3B, 
PLC/PRF/5 and HepG2 cells, respectively, while it was below 2.2fold in all other cell lines, 
including HuH7 cells.  
In conclusion, studies on R-Smad proteins show that TGF- enhances C-terminal 
phosphorylation of Smad2 and Smad3 in all HCC cell lines analyzed. The duration of 
Smad2, but not Smad3 activation is by trend negatively correlated with Smad7 mRNA 
levels. Smad3 phosphorylation was mostly prolonged but did not correlate with 
inducibility of CAGA activity, which was higher in cell lines with low Smad7 
expressions. On the other hand, Smad3/Smad4 transcriptional activity was 
accompanied by Smad3 target gene expression and induction of cytostasis by TGF-. 
3.4 Regulation of TGF- induced cytostasis 
3.4.1 Endogenous expression of proteins involved in survival signaling or 
growth control 
To investigate if the HCC cell lines are primed to the different cytostatic responses, basal 
levels of proteins, which are known to be involved in survival signaling and growth control, 
were analyzed: phosphorylation of ERK, c-Jun, and Akt (lower band) and endogenous levels 
of Akt as well as anti-apoptotic Bcl-2 and Bcl-XL. Figure 3.13 demonstrates that there was no 
survival signaling status indicating a coherent regulation mechanism of cytostatic TGF-
effects in all cell lines tested. High Akt phosphorylation (lower band) was only detected in 
HCC-T, Hep3B and FLC-4 cells, and no connection to the TGF- induced cytostatic 
response could be drawn. Similarly, basal Akt levels, which were lower in HuH7 and HuH6 
but also in HCC-M and FLC-4 cells when compared to the other cell lines, did not indicate 
cytostatic responsiveness. 
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Figure 3.13 Endogenous expression levels of different survival and growth regulating factors. HCC cell 
lines were cultured in starvation medium for 24 h. Immunoblot analysis was conducted to detect 
phosphorylated ERK, c-Jun and Akt (lower band) as well as total Akt, Bcl-2, Bcl-XL and p21. 
GAPDH was used as a loading control. The blots show representative results of two independent 
experiments. The table characterizes the cell lines regarding cytostatic response, with cells showing 
TGF- induced growth arrest in grey and cell lines additionally reacting with cell death in black. The 
gradient from white to black displays increasing basal Smad7 expression levels. 
Anti-apoptotic Bcl-2 levels were elevated in cell lines with a cytostatic TGF- response, but 
also in FLC-4 cells. In contrast, the other anti-apoptotic member of the Bcl-2 family, Bcl-XL, 
was present in all analyzed cell lines, with high levels in HepG2 and Hep3B and rather low 
amounts in HCC-M, HLE, HLF, and PLC/PRF/5 cells. Phosphorylation and consequently 
activation of ERK and c-Jun did not correlate to TGF- dependent cytostasis. However, 
interestingly, the phosphorylation status of both proteins was higher in cell lines with 
increased Smad7 mRNA levels (Figure 3.13, gradient). Only phospho-c-Jun in HuH6 cells 
deviated from this observation. Finally, p21 was predominantly found in cell lines with low 
Smad7 expression. Here, HuH6 with high p21 and Smad7 levels and PLC/PRF/5 with low 
basal Smad7 mRNA but also low p21 protein levels were an exception.  
3.4.2 TGF- induced cytostasis is Smad3 dependent 
TGF- strongly enhanced Smad3 expression and its transcriptional activity in HCC cell lines 
which were sensitive to TGF- mediated cytostasis. Strongest effects were observed in 
PLC/PRF/5, Hep3B and HuH7 cells, which did not only show TGF- dependent growth 
inhibition but also induction of apoptosis. Because TGF- mediated apoptosis is Smad3 
dependent in hepatocytes [67], the role of Smad3 during TGF- induced cytostasis was 
further delineated and was compared to Smad2. For this, RNA interference technology was 
used to target Smad2 and Smad3 mRNA. The knockdown was established over 48h before 
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continuous stimulation with TGF- for 72h. Efficient knockdown was ensured by immunoblot 
analysis after 1h of TGF- treatment (Figure 3.14, left). siRNA against Smad2 and Smad3 
significantly reduced corresponding R-Smad levels as well as their phosphorylation by 
TGF-. Admittedly, both siRNAs showed some cross reactivity with the other R-Smad’s 
mRNA, with stronger effects of Smad2 siRNA on Smad3.  
Figure 3.14 TGF- induced cell death is Smad3 but not Smad2 dependent. PLC/PRF/5 (upper panel), 
Hep3B (middle panel) were treated with 10 µM, HuH7 (lower panel) with 20µM siRNA against 
Smad2 (S2) or Smad3 (S3). An unspecific siRNA sequence (co) was used as a control. Knockdown 
was established for 48h and afterwards, each condition was either treated with or without 5ng/mL 
TGF- for 1h (immunoblot) or 3 days (cell death and proliferation). (Left) Immunoblot analysis was 
performed to detect phosphorylated and total Smad2 and Smad3 (lower band for pSmad1/3) as 
well as GAPDH as a loading control. (Middle) Cell death rates were detected using an LDH assay. 
Untreated cells for each siRNA condition were defined as 0 (grey line). TGF- treated samples are 
shown as filled bars. (Right) The same assay, but only LDH content in viable cells, was used to 
evaluate proliferation rates. TGF- treated (bars) cells were normalized to untreated (grey line) cells 
for each siRNA condition. The results show one representative of two independent experiments. 
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Figure 3.14 demonstrates that Smad3 knockdown, in contrast to Smad2 knockdown, 
efficiently blocked TGF- induced cell death (middle) and growth arrest (right) in PLC/PRF/5, 
Hep3B and HuH7 cells. In PLC/PRF/5 cells, Smad3 siRNA reduced TGF- mediated cell 
death from 26% to 4%, whereas it was decreased to 11% in cells with Smad2 knockdown. 
However, Smad2 siRNA also reduced Smad3 protein levels, which may be the reason for the 
observed protective effect. Smad3 knockdown additionally interfered with TGF- induced 
growth arrest in PLC/PRF/5 cells (right diagram). It restored TGF- decreased proliferation 
from 29% to 68%, while Smad2 siRNA resulted in only minor effects (38%). 
Basal Smad3 levels were higher in Hep3B compared to PLC/PRF/5 cells (Figure 3.5). This 
explains why the observed cross reactivity of Smad2 siRNA was not as strong in Hep3B as 
in PLC/PRF/5 cells (Figure 3.14). Smad3 knockdown almost completely abolished TGF-
induced cytostasis in Hep3B cells. Smad3 siRNA efficiently counteracted TGF- induced cell 
death from 47% to 2% and restored cell viability from 29% to 82%. In contrast, interference 
with Smad2 translation still resulted in TGF- induced cell death to 28% and growth arrest to 
50%. In HuH7 cells, inhibition of Smad3 transcription bisected TGF- induced cell death 
from 42% in control cells to 19%. Furthermore, it interfered with TGF- mediated growth 
arrest leading to 61% viable cells instead of only 32% in control samples. Smad2 
knockdown, however, did not alter the cytostatic TGF- response in HuH7 cells.   
3.4.3 Potential regulation of Smad3 by PRAJA and ELF 
ELF (2-Spectrin) may be involved in the nuclear translocation of the Smad3/Smad4 
complex and is therefore a potential regulator of Smad3 dependent TGF- signaling [182]. 
Downregulation of ELF displays one mechanism to avoid cytostatic effects of TGF-. PRAJA 
initiates ubiquitination and proteasomal degradation of ELF and thereby regulates its activity 
[183]. Hence, high PRAJA expression may lead to low ELF levels, which in turn results in 
reduced Smad3 transcriptional activity. Consequently, expression levels of both proteins 
were comparatively analyzed.   
The table and right diagram of Figure 3.15 highlight that the ELF/PRAJA ratio of the relative 
expression levels is, except for FLC-4 cells, lowest in cells with an established resistance 
against TGF- induced cytostasis. This is mainly based on varying endogenous ELF 
expression levels between the different cell lines. It was lowest in HLE, HCC-T, HLF and 
HCC-M cells (1.0-1.3fold, normalized to HLE), which were all resistant against TGF-
induced cytostasis (Figure 3.15, left diagram and table). In contrast, elevated mRNA levels 
were found in cell lines responsive to TGF- mediated cell death and growth arrest. Here, 
medium ELF expression was detected in PLC/PRF/5, HepG2 and HuH6 cells (2.5-6.0fold), 
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while highest ELF mRNA levels were assigned to HuH7 and Hep3B cells (7.8 and 11.3fold). 
Among the top six ELF expressions, only FLC-4 cells were resistant against TGF- induced 
cytostasis, with a 5.5times higher ELF expression than HLE cells. However, expression of 
PRAJA (Figure 3.15, middle diagram), which induces degradation of the ELF protein, was 
also 2times increased in FLC-4 cells in comparison to TGF- sensitive Hep3B cells. 
   
Figure 3.15 Basal mRNA levels of PRAJA and ELF in HCC cell lines. Liver cancer cell lines were cultured in 
starvation medium for 24h and afterwards, relative ELF (left) and PRAJA (middle) expression were 
detected using real time PCR with 18S rRNA as a reference gene. Results are presented as mean 
+SE of three independent experiments. (Middle) The table highlights cell lines sensitive to 
proliferation inhibition by TGF- alone (grey) or in combination with induction of cell death (black). 
(Right)The right diagram presents the ELF/PRAJA ratio of the relative expression levels shown left.    
Similar to Hep3B, other TGF- cytostasis sensitive cell lines expressed likewise low amounts 
of PRAJA, and it was almost lost in HuH7. Cytostasis resistant HLF, HCC-T, HCC-M and 
HLE cells with low ELF mRNA levels expressed low to moderate PRAJA levels (1.3-1.6fold, 
and 2.3fold in HLF cells). Finally, PLC/PRF/5 as well as HuH6 cells showed with 2.2 and 
3.1times elevated levels a rather high PRAJA expression. In general, Ct values for ELF were 
lower in HCC cell lines than the ones for PRAJA, suggesting that more ELF than PRAJA 
mRNA was present (not shown).  
In conclusion, the data in chapter 3.4 demonstrate that common survival factors such 
as ERK, Akt or Bcl-2 and Bcl-XL did not correlate with the cytostatic TGF- response 
in ten different HCC cell lines. In contrast, the finding that TGF- mediated Smad3 
transcriptional activity and inducibility of its target genes correlated with TGF-
induced cytostasis (chapter 3.3) was in line with the observation that knockdown of 
Smad3, but not Smad2, led to reduction of TGF- induced cell death and growth 
arrest. One possible mechanism of the observed resistance in other cell lines could be 
the ratio between ELF and PRAJA, which was mostly lower than in sensitive cell lines.  
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3.5 Basal cell migration is highest in cell lines with high Smad7 
expression and low TGF- induced cytostasis 
To acquire motility is an important step of cancer cells to move to new areas and to increase 
malignancy. An in vitro transwell migration assay was performed to characterize the ten liver 
cancer cell lines in regard of migratory capacity. Figure 3.16 demonstrates that three cell 
lines showed high cell motility (left diagram). While more than 40% of HLE, HLF and FLC-4 
cells migrated within 13h, all other cell lines showed low motility with migration rates below 
7%. Interestingly, all three highly motile cell lines featured high Smad7 mRNA levels (Figure 
3.16, gradient). Only TGF- sensitive HuH6 cells with the highest Smad7 expression was 
rather immotile.   
Figure 3.16 Migration capacity comes along with high Smad7 and low E-Cadherin levels. (Left) Basal 
migration rate of HCC cell lines was evaluated using a transwell assay. (Middle) HCC cell lines 
were cultured in starvation medium for 24h and subsequently, protein levels of E-Cadherin, 
phosphorylated c-Jun and GAPDH as a loading control were detected using Western blot analysis. 
The table at the right shows cell lines sensitive to TGF- induced growth arrest (grey) and 
additionally cell death (black). The gradient displays increasing Smad7 mRNA levels from white to 
black. (Right) Cell lines were cultured in starvation medium for 24h. Real time PCR analysis was 
performed to detect endogenous PAI-1 expression using 18S rRNA as a reference gene. The 
diagrams present the mean +SE of at least two independent experiments. Western blots show one 
representative of at least two independent experiments. 
Cancer cells of epithelial origin have to detach from the tight epithelial network to gain 
migratory capacity. Usually, epithelial-to-mesenchymal transition (EMT) is the underlying 
process, leading to adaption of a mesenchymal phenotype with higher degrees of freedom. 
TGF- is an important regulator of EMT, which is accompanied by downregulation of 
epithelial markers such as E-cadherin and an induction of various matrix regulating genes, 
e.g., PAI-1 [139, 140]. Immunoblot analysis (Figure 3.16, middle) revealed that highly motile 
HLE, HLF and FLC-4, but also HCC-M and HCC-T cells possessed low or undetectable 
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E-cadherin levels. In contrast, E-cadherin was heavily expressed in immotile PLC/PRF/5, 
HepG2, Hep3B, HuH7 and HuH6 cells. High cell motility was accompanied by a strong 
overexpression of EMT marker PAI-1, as seen in 420-600times higher PAI-1 mRNA levels in 
HLF, HLE and FLC-4 when compared to PLC/PRF/5 cells. In all other cell lines, PAI-1 
expression did not exceed a 17fold increased level (right diagram). 
JNK signaling is an important non-canonical TGF- signaling pathway and has been 
associated with TGF- induced apoptosis and growth arrest, but also with TGF- mediated 
proliferation, dedifferentiation and invasion. Furthermore, some of those observations have 
been linked to Smad7 [81, 114, 235]. Interestingly, Except for HuH6 cells, basal c-Jun 
phosphorylation was in general elevated in cell lines with increased Smad7 expression, 
including cells with a high motility (Figure 3.16, middle). In contrast, c-Jun activation was not 
detectable in HCC-M, HCC-T and PLC/PRF/5 with low Smad7 expression. 
Serum TGF- levels increase during liver disease progression and malignant hepatocytes 
start to produce the cytokine in relevant amounts themselves [158, 236, 237]. Next to its anti-
tumorigenic functions, TGF- is a well known booster of cancer progression as it may induce 
pro-tumorigenic processes, such as migration, invasion and metastasis (chapter 1.4). TGF-
is secreted as an inactive form and is activated by several proteins and factors (chapter 
1.1.1). Hence, secretion of active and total amounts of TGF- by HCC cell lines was of 
interest (Figure 3.17).  
Figure 3.17 Active TGF- levels are higher in HCC cell lines insensitive to TGF- induced cytostasis.
(Left) TGF- reporter cell line MFB-F11 was used to evaluate the total amount of active TGF-
secreted to the medium by liver cancer cell lines. Secreted TGF- was normalized to protein 
content in adherent cells. Cells were grouped in cell lines sensitive (HepG2, HuH6, PLC/PRF/5, 
HuH7 and Hep3B) or resistant (HCC-T, FLC-4, HLE and HLF) to TGF- induced growth arrest and 
cell death. (Right) In addition to mature TGF-, the total amount of TGF- was detected after 
activation of latent TGF-. The diagram shows the ratio of total to active TGF-. The data are 
presented as mean +/- SE of three independent experiments.  
TGF- amounts in the medium were normalized to the total protein amount of adherent cells 
and for further evaluation, cells were grouped in cell lines sensitive (HepG2, HuH6, 
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PLC/PRF/5, HuH7 and Hep3B) or resistant (HCC-T, FLC-4, HLE and HLF) to TGF- induced 
cytostasis. HCC-M cells were excluded from this experiment because some component of 
the conditioned medium interfered with the assay. Sensitive cells secreted by trend lower 
amounts of active TGF- in comparison to resistant cell lines (left diagram). However, this 
finding was only significant (p = 0.032) when Hep3B cells, the sensitive cell line with the 
highest active TGF- levels, were excluded. Lowest amounts of mature TGF- in cell lines 
resistant to TGF- induced cytostasis were detected in HCC-T cells, which showed similar 
levels to TGF- sensitive cells. Furthermore, the right diagram of Figure 3.17 demonstrates 
that resistant HCC cell lines activated TGF- at a higher percentage. The ratio of total to 
activated TGF- is by trend lower in these cells when compared to cell lines sensitive to 
cytostatic effects of TGF-.  
In summary, migratory capacity in HCC cell lines correlated with reduced E-cadherin 
levels, high c-Jun activation as well as elevated Smad7 and PAI-1 expression and, by 
trend, more activated TGF- in the medium.  
3.6 Smad7 overexpression in human liver cancer samples 
TGF- signaling is frequently defective during hepatocarcinogenesis. Smad7 is an important 
modulator, but also cross-talk mediator, of TGF- signaling (chapter 1.1.4 and 1.4.). Hence, 
Smad7 expression in human HCC samples was compared to “normal” (non tumorigenic) liver 
tissue from the same patient. Expression analysis of 133 samples from China and Germany 
was performed, of which 6 Chinese samples were not compared to matching normal liver 
samples but to the mean of two samples from other patients without HCC. Information about 
the patients is summarized in Table 3.1.  
For expression analysis of Smad7, real time PCR was performed and 18S rRNA was used 
as a reference gene. Calculated Smad7 expression in tumors was normalized to Smad7 
expression of the corresponding non-tumorigenic liver specimen. Samples were only 
included in the study if Ct-values of 18S rRNA were similar (within 1 cycle) in matched 
tumorigenic and adjacent liver tissue samples, or, as in seven cases, when larger differences 
were confirmed with a second reference gene (2-microglobulin). Smad7 overexpression 
was assumed when the expression levels in tumorigenic tissue was more than 1.2fold 
increased as compared to the control tissue. 
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Chinese specimen German specimen 
Total 63 70 
      
Gender     
Male  51 36 
Female 4 18 
Unknown 8 16 
      
Age (mean) 25-75 years (49.0) 20-80 years (61.1) 
> 50 42.6% 82.5% 
 50 57.4% 18.5% 
Unknown 7 15 
      
Etiology     
HBV 61 5 
HCV 1 3 
HBA 0 2 
Alcohol 4 (all HBV) 12 (1x HBV, 1x HCV) 
      
Cirrhosis - yes/no 51/10 17/48 
Unknown 2 5 
Tumor size      
> 5cm 34 33 
 5cm 21 15 
Unknown 8 22 
Cell differentiation 
Well - moderate (G1/2) 36 24 
Poor - undifferentiated (G3/4) 19 22 
Unknown 8 24 
AFP (ng/ml)     
> 50 34 15 
 50 20 21 
Unknown 9 34 
Table 3.1 Clinicopathological variables of HCC patients from Germany and China. 
Unchanged levels were defined as mRNA levels between 0.8 and 1.2fold, whereas a 
reduction of expression to less than 0.8fold was rated as repressed. Figure 3.18 shows that 
Smad7 mRNA levels were elevated in the majority (58.6%) of all analyzed HCC samples, 
while they were repressed in only 24.1% and unchanged in 17.3%. A more detailed analysis 
revealed that Smad7 overexpression in HCC varied from 1.22 to 38.7fold, in which half of 
the samples (51.2%) expressed levels between 2 and 10fold. 28.2% were only slightly 
elevated with Smad7 mRNA being 1.2 to 2 fold increased. After all, about one fifth of all 
Smad7 overexpressing HCC samples possessed very high levels (>10fold). In contrast, 
cancer specimens with reduced Smad7 expression were less spread and only one showed 
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expression below 0.1fold. Similar to the Smad7 overexpressing samples, the majority of all 
samples with reduced Smad7 (56.2%) expression exhibited 2-10 times reduced Smad7 
levels (0.5-0.1fold). However, compared to HCC samples with slightly elevated Smad7 levels 
(28.2%), a higher percentage of HCCs (40.6%) showed a minor Smad7 repression with less 
than two-fold inhibition (> 0.5fold).  
Figure 3.18 Smad7 expression is increased in hepatocellular and intrahepatic cholangiocellular 
carcinoma. Real time PCR expression analysis of Smad7 and 18S rRNA as a reference gene was 
performed for 133 matched normal liver and HCC (upper diagram) or intrahepatic 
cholangiocarcinoma (iCCC, lower right) patient samples. The grey lines in the upper diagram 
indicate 2 or 10times increased or reduced Smad7 expression. Six analyzed HCC samples were 
compared to the mean of two normal liver samples from other persons. Four cancer/adjacent liver 
tissue samples included in the HCC analysis were of mixed origin (HCC/iCCC). The circle diagram 
shows the percentage and number of HCC samples with underrepresented, overexpressed or 
unchanged Smad7 levels.  
Next to biopsies of hepatocellular carcinoma, a limited number of intrahepatic 
cholangiocarcinoma (iCCC), a cancer of the liver bile duct system accounting for about 
5-10% of all primary liver cancers [238], were analyzed. Interestingly, Smad7 levels were 
increased in all iCCC samples investigated when compared to adjacent liver tissue, ranging 
from 1.3 to 10.7fold (Figure 3.18, lower right diagram).  
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Figure 3.19 Smad7 expression correlates with tumor size in HCC patient samples from China. 
Information about tumor size was available for 103 of 133 HCC samples as contained in Figure 
3.18. 55 HCC samples from China (left) and 48 from Germany (right) were grouped in tumors 
smaller than/equal to or bigger than 5cm. Diagrams show percentages of samples with increased 
(black), decreased (white) or unchanged (grey) Smad7 levels for small and large tumors as well as 
for the sum of both groups.  
Seventy paired HCC/”normal” liver samples were obtained from Germany and 63 from 
China. The majority of Chinese samples were evaluated in collaboration with Prof. Gao and 
Dr. Gu (Department of Laboratory Medicine, Eastern Hepatobiliary Hospital, Second Military 
Medical University, Shanghai, China). Overexpression of Smad7 was found in 54.3% and 
63.5% of German and Chinese samples, respectively (not shown). Comprehensiveness of 
patient data was varying for the different patient samples. Hence, correlation analysis 
between Smad7 expression and different clinical data was only conducted for tumor size and 
cell differentiation. Tumor size was known for 103 patients, 55 from China and 48 from 
Germany (Figure 3.19), in which Smad7 was overexpressed at a lower frequency when 
compared to all samples: 47.9% and 61.8% instead of 54.3% and 63.5%, respectively. The 
samples were sorted in two groups, at which one contained samples with tumors sized 
bigger than 5 cm (largest dimension), while tumors smaller or equal to 5 cm were allocated to 
the second group. Interestingly, there was a strong difference in the Smad7 pattern in 
samples collected in China (Figure 3.18, left diagram), whereas in those from Germany, 
percentages of unchanged, elevated or decreased Smad7 were similar in the two groups. In 
Chinese samples, overexpression was found in only 38.1% of small tumors but in a 
remarkable 76.5% of large HCCs. This increase in overexpression was mainly at the 
expense of unmodified Smad7 levels. For Chi-Square analysis the samples within one group 
(small versus large tumor) were sorted in samples with or without Smad7 overexpression. 
Differences in the Chinese sample set turned out to be significant (2 = 8.1, p = 0.004). 
Hence, Smad7 overexpression significantly correlated with tumor size in Chinese but not 
German (2 = 0.01, p = 0.91) HCC tissue samples. In line with that, Smad7 overexpression 
in intrahepatic CCC from Germany strongly correlated to increasing tumor size (r = 0.82, 
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p < 0.01; data not shown). Correlation analysis between cell grading and Smad7 expression 
identified similar Smad7 expression patterns in well/moderately differentiated and poorly 
differentiated/undifferentiated HCC specimens of China as well as Germany (2 = 0.47, 
p = 0.49 and 2 = 0.03, p = 0.87). Noteworthy, HCC in samples from Germany did not arise 
from HBV or HCV infection in most cases, whereas the broad majority of the Chinese 
samples were collected from patients with HBV infection (Table 3.1). 
In summary, the evaluation of HCC patient samples from Germany and China show 
that Smad7 is frequently overexpressed in tumorigenic tissue with a strong 
correlation to increased tumor size in Chinese samples. This can possibly be ascribed 
to HBV infection as cancer etiology.   
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4 DISCUSSION
4.1 TGF- signaling patterns in liver cancer cell lines  
TGF- is a well known inducer of growth arrest and apoptosis in various cell types, e.g., 
epithelial cells and hepatocytes [71, 123, 124], and, hence, a suppressor of tumor 
development in different cancer systems. Intriguingly, TGF- was shown to exert 
protumorigenic functions in various tumors, including HCC (chapter 1.4). It is thought that 
neoplastic cells may develop different responses to this ambiguous role of TGF-. The 
impairment of TGF- signaling key components results in total inhibition of TGF- signaling. 
Abrogation of components further downstream, however, may specifically amputate 
cytostatic TGF- signaling while protumorigenic pathways are still functional.  
In this study, nine different HCC cell lines (HCC-M, HCC-T, HepG2, Hep3B, HuH7, 
PLC/PRF/5, HLE and HLF) and the hepatoblastoma cell line HuH6 were analyzed with 
respect to integrity and functionality of TGF- signaling, with a special focus on cytostatic 
effects of TGF- (summarized in Figure 4.1, page 84).   
4.1.1 Cytostatic TGF- impact varies in HCC cell lines  
The anti-tumorigenic character of TGF- is frequently lost in cancers. TGF- levels in serum 
are rising during progression of liver disease [236, 237]. Therefore, the cytostatic response of 
different HCC cell lines to continuous TGF- stimulation was evaluated (Figure 3.1 and 3.2) 
and could be roughly assigned into two groups. TGF- rapidly induced cell death and growth 
arrest in Hep3B, HuH7 and PLC/PRF/5, whereas HepG2 and HuH6 cells solely responded 
with a delayed inhibition of cell growth. Inhibition of proliferation was accompanied by 
repression of pro-proliferative c-Myc and induction of anti-proliferative p21. Moreover, TGF-
dependent cleavage of PARP and Caspase-3, and enhanced Bim expression (Figure 3.12) 
indicated an involvement of the apoptotic cascade in the observed induction of cell death. 
The second group consisted of cell lines which were resistant against TGF- induced 
cytostasis: HCC-M, HCC-T, FLC-4, HLE and HLF. In two of these cell lines, TGF- even 
exerted pro-proliferative (HCC-T) or anti-apoptotic (HCC-M) effects. In line with this, TGF-
was first identified as a growth factor which induces proliferation in mesenchymal cells [185]. 
Since then, tumors of epithelial origin were found to acquire this behavior in response to 
TGF- [186, 239]. This emphasizes findings that cancer cells may use TGF- for their own 
benefit, once the cytostatic TGF- branch is disrupted. 
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TGF- induces cell death and growth arrest in Hep3B, HuH7 and 
PLC/PRF/5 and inhibits proliferation in HepG2 cells.  
[174, 187, 240-244]  
HLE and HLF cells are resistant against TGF- induced cytostasis [242] 
TGF- enhances proliferation in HCC-M and HCC-T cells [239] 
Table 4.1 Publications regarding cytostatic TGF- response in HCC cell lines used in this study. 
The described TGF- responses were already known for most cell lines and could be 
confirmed by the results of this study (Table 4.1). A notable exception was the HCC-M cell 
line, for which a weak pro-proliferative effect of TGF- was described [239]. In contrast, the 
MMT assay used in this study suggested unaltered proliferation. Proliferation analysis using 
an LDH assay, however, indicated an increase of viable HCC-M cells to 108% (p = 0.016, 
data not shown) after three days TGF- treatment. HuH6 and FLC-4 are cell lines not well 
analyzed regarding their TGF- response. To my knowledge, this is the first time that effects 
of TGF- on proliferation and apoptosis were delineated in these two cell lines.  
4.1.2 Contribution of canonical TGF- signaling components to cytostatic 
response and conversion to a more malignant phenotype 
TGF- exerts its anti-tumorigenic functions via different canonical and non-canonical 
mechanisms. To identify possible underlying reasons for the observed resistances, a detailed 
dissection of canonical TGF- signaling was performed.  
4.1.2.1 TGF- receptors 
Mature TGF- dimers activate canonical signaling through inducing the formation of a 
heteromeric receptor complex. Altogether, endogenous mRNA levels of TGF- receptor II 
(TRII) were elevated in liver cancer cell lines which were responsive to cytostatic effects of 
TGF- (Figure 3.4). The second component of the receptor complex, TRI, was 
characterized by a more stable basal expression. These results suggest that the quantity of 
TRII may dictate the cell fate upon TGF- treatment. In fact, hepatocyte proliferation in 
growing livers is enhanced in heterozygous TRII knockout mice as compared to wild type 
animals. Further, the knockout animals are more responsive towards chemically induced liver 
cancerogenesis [245]. In line with that, TGF- receptor levels increase in primary rat 
hepatocytes during culture, which correlates with a rising sensitivity towards growth inhibition 
by TGF- [246].  
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The TRII/TRI mRNA ratio pointed out that basal TRII expression was higher than that of 
TRI in most HCC cell lines. Overall, this ratio was higher in cytostasis sensitive cell lines in 
comparison to resistant cells (Figure 3.4). TGF- impact on TGF- receptor expression 
created a totally different picture (Figure 3.6). Minor inhibition of TRII expression was 
observed in most cell lines after stimulation with TGF-, whereas TRI mRNA levels were 
strongly increased in cell lines responding to TGF- with cell death induction (Hep3B, HuH7, 
and PLC/PRF/5). Different TGF- type I receptors compete for the same type II receptor. In 
the case of TRII, TRI (ALK5) is the main mediator of TGF- signaling. However, ALK1, 
ALK2 and ALK3 are also able to interact with TGF- activated TRII, leading to 
phosphorylation of Smad1 and Smad5. This process, which is linked to proliferation, 
anchorage-independent growth and migration, is TRI dependent and simultaneously leads 
to decreased TRI signaling via Smad2 and Smad3 [21-24]. TGF- induced Smad1 
phosphorylation in all cell lines analyzed (Figure 3.11), suggesting an activation of a type I 
receptor other than TRI. The observed induction of TRI expression may therefore result in 
a higher probability of TRI-TRII-complex formation, possibly leading to higher susceptibility 
to TGF- induced apoptosis and growth arrest. Conversely, low TRII levels and 
unresponsiveness to TGF- induced TRI expression may provide protection against TGF-
induced cytostasis. The role of TRI during hepatocarcinogenesis is still unsolved as 
conflicting findings have been described [243, 247]. In line with the result presented here, a 
reduction of TRII levels is frequently found in HCC [158, 174, 243, 247], but mainly during 
advancing dedifferentiation [174], questioning its importance for establishing a resistance 
against cytostatic effects of TGF- during early hepatocarcinogenesis. These observations 
coincide with the results presented here and elsewhere [174], in which the highest TRII 
expression was observed in well differentiated cell lines (in this study: Hep3B, HepG2, 
PLC/PRF/5 and HuH7). 
In conclusion, downregulation of TGF- receptor II and inhibition of TGF- dependent 
inducibility of TGF- receptor I may protect HCC cell lines against cytostatic effects of 
TGF-. A shift of TRI towards other TGF- type I receptors may provide a mechanism 
that directs TGF- signaling towards tumorigenic effects.  
4.1.2.2 TGF- and Smad7  
TGF-1, according to current knowledge, is the main player of the three cytokine isoforms in 
the liver and initiates canonical signaling and cross-talk to other signaling pathways. Smad7 
is able to counteract canonical TGF- signaling at several levels (chapter 1.1.4.1) and to 
direct the effects of TGF- in different directions (chapter 1.1.4.3). Therefore, basal Smad7 
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as well as autocrine TGF-1 levels are important modulators of TGF- signaling. Smad7 
mRNA levels varied considerably between the ten different liver cancer cell lines but, 
interestingly, strongly correlated with TGF-1 expression (Figure 3.3). Cell lines which were 
sensitive to TGF- mediated cytostasis expressed comparably low Smad7 and TGF- levels. 
In the group of resistant cell lines, only HCC-M and HCC-T showed similar low levels of 
TGF- and Smad7. Those two cell lines took an exceptional position throughout almost the 
whole study, which will be discussed in detail in chapter 4.1.2.4. HuH6 cells with a moderate 
sensitivity to TGF- induced growth arrest showed high Smad7 and TGF-1 expression, but 
rather low amounts of mature TGF- levels (Figure 3.17) in the medium. HuH6 cells are 
derived from a hepatoblastoma [225] and therefore, may behave differently from HCC cell 
lines. Low Smad7 levels in TGF- sensitive cell lines suggest that Smad7 overexpression 
inhibits TGF- induced cytostasis in HCCs. Indeed, protective effects of Smad7 against 
cytostatic TGF- functions were shown in Hep3B and HuH7 cells [116, 241]. Once cytostatic 
effects of TGF- are inhibited, cancer cells may benefit from tumorigenic TGF- processes 
(chapter 1.4.1 and 1.4.2). In line with that, endogenous activation of latent TGF- was by 
trend increased in HCC cell lines with an established resistance against TGF- induced 
cytostasis (Figure 3.17). These findings suggest the following mechanism in HCC cell lines. 
Elevated Smad7 expression provides protection against cytostatic effects of TGF- and 
hence allows increased activation of mature TGF-. However, this enhanced turnover of 
TGF- requires intensified production of the cytokine, which explains elevated TGF- mRNA 
levels and the observed positive correlation to Smad7. In fact, elevated TGF- levels is a 
common feature in various cancer entities [153-157], including HCC, in which malignant 
hepatocytes were identified as one source of TGF- production [158, 159].  
The amount of active TGF- is increased in invasive HCC cell lines [192] and TGF- serum 
levels in HCC patients correlate with invasiveness [248]. Further, autocrine TGF- signaling 
was identified as important for increased cell motility, as a TRI inhibitor (LY2109761, inhibits 
canonical and non-canonical signaling [249]) restores expression of E-cadherin and 
efficiently inhibits migration and invasion of HLE and HLF cells in vitro and metastasis of HLE 
cells in vivo [191, 250]. Consistently, the three HCC cell lines with a high migratory capacity 
(HLE, HLF and FLC-4, Figure 3.16) secreted the largest amounts of mature TGF- within the 
TGF- induced cytostasis resistant group. This motile phenotype was accompanied by low 
E-cadherin, high PAI-1 and Smad7 expression and high c-Jun activation. Interestingly, 
activation of the JNK pathway by TGF- is Smad7 dependent and linked to TGF- induced 
motility [81, 251] (further discussed in chapter 4.1.3.2). Further, PAI-1 and active c-Jun 
correlate with low grade differentiation and poor prognosis in human HCC, respectively [79, 
252, 253], which is in agreement with the results presented here. Some immotile cell lines 
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showed high c-Jun activity as well, but no repression of E-cadherin. In contrast, HCC-M and 
HCC-T cells featured low levels of epithelial marker E-cadherin, but also of Smad7 and 
active c-Jun. Overall, the findings suggest that migratory capacity of HCC cell lines 
coincidences with repression of the epithelial marker E-cadherin and with enhanced levels of 
Smad7, active c-Jun and mesenchymal marker PAI-1. Interestingly, all those factors can 
directly or indirectly be regulated by TGF-, which is in line with rather high levels of mature 
TGF- in the supernatant of motile cells.   
4.1.2.3 Receptor-Smads and Smad4  
TGF- induces phosphorylation and, thereby, activation of receptor (R-) Smads, which then 
form a transcription factor complex with Smad4. Analysis of R-Smad2 and 3, and common 
mediator Smad4 in HCC cell lines suggests that basal expression levels did not contribute to 
the observed differences in cytostatic TGF- response (Figure 3.5). Smad2 and Smad4 
mRNA and protein were equally distributed between the different cell lines. In contrast, 
Smad3 levels varied strongly but without any correlation to inducibility of cytostasis by 
TGF-. TGF- dependent induction of Smad3 expression, however, was exclusively found in 
cell lines which were sensitive towards TGF- induced cytostasis, while mRNA levels of 
Smad2 and 4 remained unaltered (Figure 3.7 and 3.8). This indicates a higher relevance of 
Smad3 than Smad2 for cytostatic effects of TGF-, which was confirmed using RNA 
interference technology in Hep3B, HuH7 and PLC/PRF/5 cells. TGF- strongly induced 
cytostasis in these cell lines. Smad3, unlike Smad2, knockdown efficiently inhibited TGF-
induced cell death and partly restored the original proliferation rates. In agreement with this, 
Smad3, unlike Smad2, was identified as a main mediator of TGF- induced apoptosis and 
growth arrest in hepatocytes and Hep3B cells [67, 128, 129]. Furthermore, Smad3 knock-
down increases susceptibility to chemically induced liver tumors in vivo, probably due to 
protection against induction of cytostasis by elevated TGF- levels in neoplastic areas [129]. 
Intriguingly, Smad3 mutations are not reported for HCC [254]. Smad2 mutations are detected 
in 5% and, although reduced levels of Smad4 occur frequently, a depletion of Smad4 protein 
is observed in only 10% of all HCCs [173, 255]. Accordingly, other mechanisms than 
R-Smad or Smad4 mutations likely contribute to the development of resistances against 
cytostatic effects of TGF- (e.g., Smad7 overexpression, TRII downregulation). 
R-Smads are activated by phosphorylation at the C-terminus. TGF- induced Smad2 
activation was found in all cell lines (Figure 3.10 and  3.11), but with varying signal durations. 
Smad2 phosphorylation was by trend prolonged in cell lines with lower Smad7 expression 
and transient in cells with elevated Smad7 mRNA levels. This negative correlation between 
Smad7 and the duration of Smad2 activation suggests that Smad7 is able to not only inhibit 
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R-Smad activation, but also alter canonical TGF- response by abbreviation of Smad2 
activation. TGF- signaling can be disrupted at various levels (chapter 1.1.4.3). Hence, it was 
of interest if the inducibility of R-Smads correlates with their transcriptional activity. TGF-
induced Smad2 transcriptional activity was high in some, but not all, cytostasis sensitive cell 
lines (HuH7, PLC/PRF/5 and HepG2). Contrarily, it was not inducible in resistant HCC-M, 
HCC-T and FLC-4 cells, but preliminary experiments suggest a high autocrine stimulation of 
Smad2 (but not Smad3) transcriptional activity (data not shown). TGF- quickly induced 
Smad3 phosphorylation in all cell lines. Nevertheless, in contrast to Smad2, the signal 
duration was prolonged in most cell lines (Figure 3.11) and therefore did not correlate with 
the Smad7 expression. TGF- induced Smad3 transcriptional activity, however, was highest 
in all cell lines sensitive to cytostatic effects of TGF-, showing a better coincidence with 
inducibility of cytostasis than the one of Smad2. This is in line with the results of the Smad2/3 
knockdown experiments (see above).  
Functions of Smad2 and, especially, Smad3 dependent TGF- signaling can be divergent 
and context dependent [128, 256-258], highlighting the necessity to carefully analyze each 
signaling branch in the HCC cell lines. In pancreatic cancer cells with TGF- induced 
transient Smad2 activation, the cytostatic sensitivity is decreased as compared to cell lines 
with prolonged Smad2 signaling. This transient Smad2 response results in reduced effects of 
TGF- on expression of cell cycle control proteins (e.g., induction of p21), while the TGF-
induced expression of other target genes, such as Smad7 and PAI-1, is not affected [259]. 
As discussed above, elevated basal Smad7 expression resulted in transient Smad2 
activation by TGF-, which was accompanied by resistance against cytostatic effects of 
TGF- and reduced (but in most cases not depleted) Smad2 transcriptional activity in HCC 
cell lines. Similarly, TGF- induced Smad3 transcriptional activity was reduced but seldom 
lost in those cell lines. Downregulation of TGF- receptor II, as seen in various cancers, may 
not only interfere with the cytostatic TGF- branch, but also with pro-tumorigenic signaling. 
Smad7, on the other hand, is not only an inhibitor of canonical signaling, but also an 
important scaffold protein for several non-canonical TGF- pathways, which mostly exert 
protumorigenic effects (chapter 1.1.4 and 3.4.1). Hence, Smad7 overexpression could 
display a mechanism to attenuate a TGF- signal below the threshold for cytostasis 
induction, while more sensitive or cross-talking pathways are still functional. This could be of 
importance as, for example, TGF- induced Smad3 activity is not only linked to induction of 
cell death, but also to EMT in hepatocytes [128]. This hypothesis is supported by the fact that 
HCC cell lines with high Smad7 levels tended to a) express increased levels of TGF-
(Figure 3.3) and b) activate the latent cytokine at a higher rate (Figure 3.17Figure 3.17). 
These enhanced TGF- levels could in turn be used to induce protumorigenic effects of 
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TGF- (e.g., migration, see chapter above) in an autocrine manner via non-canonical but 
also via (not fully abrogated) canonical signaling pathways.  
Taken together, the results discussed in chapter 4.1.2.2 and 4.1.2.3 indicate that 
attenuation of canonical TGF- signaling may offer a protection against cytostatic 
effects of the cytokine, whereas other TGF- features could remain functional. By this, 
TGF-, which mainly acts as a tumor suppressor in normal epithelial cells, can be 
converted into a tumor promoter in cancers of epithelial origin. Interestingly, elevated 
TGF- expression predominantly occurs in cell lines with a resistance against TGF-
induced cytostasis and coincides with high Smad7 levels, which may attenuate TGF-
signaling. 
4.1.2.4 HCC-M and HCC-T – cell lines with a special TGF- signature  
Overall, the cell lines can be grouped in cells being responsive or resistant to TGF- induced 
cytostasis, which is accompanied by specific features (overview and discussion in chapter 
4.1.4). HCC-M and HCC-T cells, however, combined characteristics of both groups. They 
shared low Smad7 mRNA levels and a prolonged TGF- induced activation of Smad2 with 
TGF- sensitive HCC cell lines, but they were resistant against TGF- mediated cytostasis 
and had many other similarities to cell lines expressing high levels of Smad7. For example, 
they expressed low levels of TRII and were unresponsive to TGF- mediated target gene 
induction (Smad3, PAI-1, Smad7 and TRI), repression of c-Myc and induction of p21. 
Interestingly, out of all cell lines analyzed, only HCC-T and HCC-M cells showed even 
inverted effects of TGF- in regard of cytostasis, as seen in increased proliferation in HCC-T 
and reduced basal cell death in HCC-M cells upon stimulation with TGF-.  
The outcome of a TGF- signal can be dependent on the amount of TRII (chapter 4.1.2.1). 
HCC-M and HCC-T expressed the lowest TRII levels of all cell lines analyzed. Repression 
of TRII, as alternative to overexpression of Smad7, possibly provides another mechanism to 
establish a resistance against cytostatic effects of TGF-, which could result in a signal 
below the threshold for induction of cytostasis. However, TGF- treatment led to prolonged 
phosphorylation of Smad2 and 3 (Figure 3.10 and 3.11), indicating a successful signal 
transmission into the cell. Both cell lines, nevertheless, were under the top three with the 
lowest TGF- induced Smad2 and Smad3 transcriptional activity (Figure 3.10 and 3.11). 
Noteworthy, preliminary data suggest a high autocrine Smad2, but not Smad3 transcriptional 
activity (data not shown). These results imply a functional Smad2 pathway and, in contrast, 
aberrant Smad3 signaling, which is disrupted downstream of Smad3 activation. In line with 
that, TGF- induced apoptosis of hepatocytes is linked to Smad3 [67]. The observed 
Discussion  79 
resistance to TGF- induced cell death in HCC-T and HCC-M cells may be related to a low 
ELF/PRAJA ratio (Figure 3.15). ELF assists with the nuclear translocation of Smad3, but has 
no impact on Smad2 signaling. Because PRAJA mediates proteasomal degradation of ELF 
and Smad3 (detailed discussion in chapter 4.1.3.3), low ELF and high PRAJA levels (low 
ratio) may result in reduced Smad3 signaling downstream of its activation, while Smad2 
signaling is not affected.  
     
4.1.3 Impact of cross-talk components and signaling regulators on TGF-
induced cytostasis   
So far, besides direct modulations of TGF- signaling components, various other 
mechanisms were identified that shed light on how cancer cells circumvent TGF- induced 
anti-tumorigenic effects. The following chapters will discuss a potential involvement of those 
mechanisms in the analyzed HCC cell lines.  
4.1.3.1 Bcl-2 family and p21 – proteins with direct impact on cell survival and 
proliferation 
The Bcl-2 family consists of pro- (e.g., Bim) and anti-apoptotic (e.g., Bcl-2 and Bcl-XL) family 
members, and the balance between those two groups can decide cell fate. Endogenous 
levels of anti-apoptotic Bcl-XL did not correlated with inducibility of apoptosis by TGF- in the 
liver cancer cell lines analyzed. Surprisingly, anti-apoptotic Bcl-2 was by trend higher 
expressed in cell lines sensitive towards TGF- mediated cell death. However, TGF-
decreases Bcl-2 and Bcl-XL levels during induction of apoptosis in hepatocytes, while 
expression of pro-apoptotic Bim is increased [71, 130]. Similarly, TGF- strongly enhanced 
Bim expression in HCC cell lines responsive to TGF- induced cell death (Figure 3.12), 
which probably contributes to switch the balance from survival towards cell death.    
Expression of p21, an inhibitor of the cell cycle, is induced during TGF- mediated growth 
arrest [34, 36, 135]. In contrast, c-Myc usually exerts pro-proliferative functions and may be 
downregulated by TGF- [137, 138]. Smad7 inhibits basal and TGF- induced p21 
expression and has opposing effects on c-Myc in human adenocarcinoma cell lines [235]. 
Accordingly, HCC cell lines with a responsiveness to TGF- mediated regulation of c-Myc 
and p21 (Figure 3.1) expressed, in general, low Smad7 levels (Figure 3.3). Furthermore, 
except for PLC/PRF/5 and HuH6 cells, basal p21 protein levels were high in cell lines with 
decreased Smad7 amounts (Figure 3.13). This is in line with the described suppressive 
effects of Smad7 on p21 and on TGF- induced growth arrest.    
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4.1.3.2 The TGF--MAPK- and Akt-axis 
Next to Smad dependent signaling, TGF- utilizes various non-canonical signaling cascades,
including several survival pathways, in a cell type and circumstance dependent manner 
(chapter 1.1.3).  
Cross-talk with the Ras-Raf-MEK-ERK pathway 
Cross-talk of TGF- with ERK signaling is well recognized and is involved in EMT, migration 
and invasion of various normal and (epithelial) cancer cells [62, 63, 251, 260]. In human 
HCC, MEK1/2 (MKK1/2) and ERK expression and phosphorylation are linked to proliferation 
and disease progression [261, 262]. Furthermore, hyperactive Ras activates ERK and thus 
inhibits TGF- induced cytostasis in immortalized hepatocytes, while the EMT process 
remains functional and is even enhanced [263]. In the liver cancer cell lines analyzed, 
endogenous ERK phosphorylation increased with rising Smad7 mRNA levels and was well 
detectable in motile and TGF- induced cytostasis resistant HLE, HLF and FLC-4 cells 
(Figure 3.13). However, similar activity was also found in TGF- sensitive Hep3B, HuH7 and 
HuH6 cells. Interestingly, EGF receptor HER2, via Ras-Raf-ERK, is able to induce Smad7 
expression in different cancer cell lines [109]. Even though HER2 overexpression is seldom 
found in HCC [264, 265], these publications demonstrate a possible impact of ERK on 
Smad7 levels. ERK hyperactivity is found in 39-100% of all HCCs, especially in those related 
to HBV or HCV [180, 252, 261, 262, 266, 267]. Interestingly, TGF- itself is able to induce 
ERK activity [59-61]. In the analyzed HCC cell lines, TGF-1 expression correlated with 
Smad7 expression and, by trend, survival. Furthermore, ERK activation was increased in cell 
lines with enhanced Smad7 expression. Hence, it would be interesting to analyze if 
enhanced Smad7 expression in the HCC cell lines can be ascribed to increased ERK 
activity, and if the high TGF- expression itself contributes to this by induction of ERK.   
The TAK1-MKK-JNK pathway 
Except for the hepatoblastoma cell line HuH6, amounts of activated c-Jun were also 
increased in cell lines with elevated Smad7 expression (Figure 3.13). TGF- induces MAPK 
JNK, an upstream signaling component of c-Jun, in epithelial and mesenchymal cells [65, 
67]. Interestingly, Smad7 is probably an important scaffold protein, which facilitates the 
interaction of TRI with upstream components (TRAF6-TAK1-MKK) of JNK and c-Jun [68] 
(chapter1.1.4.3). This possibly explains the elevated c-Jun activation in HCC cell lines with 
high Smad7 expression. Smad7 overexpression in the well differentiated colon 
adenocarcinoma cell line FET results in a more malignant and faster growing phenotype in 
vivo. This is accompanied by basal c-Jun phosphorylation, which is further enhanced by 
TGF- treatment. Simultaneously, growth limiting TGF- signaling is repressed [235]. 
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Similarly, JNK is crucial for TGF- induced breast cancer cell motility in vitro [251]. Positive 
phospho-c-Jun staining is found in human HCC and its intensity is increasing during 
dedifferentiation [252]. Other potentially pro-tumorigenic effects of c-Jun in the liver were 
discovered in mice, as seen in reduced proliferation, increased apoptosis and impaired liver 
regeneration after knockdown of c-Jun in hepatocytes [268]. Consistently, high c-Jun 
phosphorylation and Smad7 and TGF-1 expression were detected in HCC cell lines with a 
high migratory capacity and resistance against cytostatic effects of TGF- (Figure 3.16). 
However, similar c-Jun activation was also observed in some cytostasis sensitive cell lines. 
c-Jun is a component of stress response pathways and hence, has been linked to anti-
tumorigenic effects as well. Smad7 is able to induce c-Jun activity in epithelial kidney and 
lung cell lines, which is linked to increased apoptosis after serum starvation [114]. Hence, the 
cross-talk between TGF-/Smad7 and JNK is context dependent, which possibly explains the 
hyperactivity of c-Jun found in both, Smad7 overexpressing cell lines insensitive and 
responsive to TGF- induced cell death.  
R-Smad linker phosphorylation by ERK and JNK signaling pathways 
As discussed above, TGF- may impact ERK and JNK signaling. Intriguingly, those 
pathways are in turn able to directly modify Smad activity by phosphorylation of specific sides 
within the Smad linker regions (chapter 1.1.3). EGF stimulation, for example, leads to the 
phosphorylation of ERK consensus sites and results in retention of Smad2 and 3 in the 
cytoplasm [78]. During HCV related liver disease progression in patients, TGF- signaling is 
switched from C-terminal to JNK-dependent linker phosphorylation of Smad3. Furthermore, 
patients with fibrosis carry a higher risk to suffer from cancer if this Smad3 linker 
phosphorylation is elevated. Inhibition of JNK activity interferes with TGF- induced Smad3 
linker phosphorylation and invasion in primary hepatocytes. In parallel, the growth limiting 
TGF- branch (C-terminal Smad3 phosphorylation and p21 induction) remains functional and 
its activity is even enhanced after inhibition of JNK [81]. Similar findings were made in HBV 
related liver disease progression [82]. These observations suggest that canonical TGF-
signaling does not only suffer from a shift towards non-canonical signaling, but that this shift 
may result in an additional interference with (ERK) or modification of (JNK) R-Smad 
signaling. Hence, to fully delineate R-Smad signaling in the used liver cancer cell lines, an 
analysis of linker phosphorylation and the contribution of JNK and ERK, but also of TGF-
itself is indispensable. 
The PI3K/Akt signaling pathway 
TGF- modulates Akt signaling in certain contexts. In several cell types, TGF- stimulates 
Akt activity, resulting in enhanced survival and induction of proliferation and EMT [69-72]. In 
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contrast, in cells in which the cytostatic TGF- branch dominates, TGF- induced apoptosis 
is accompanied by inhibition of Akt activation [73, 74]. Hepatocytes cultured on a stiff matrix 
are characterized by fast dedifferentiation and decreased TGF- induced apoptosis when 
compared to well differentiated hepatocytes cultured between two soft collagen layers 
(collagen sandwich). This reduced sensitivity to cytostatic effects of TGF- can be attributed 
to enhanced basal and TGF- induced Akt phosphorylation [71]. Consistently, Akt is 
overexpressed and hyperactive in HCC [179, 180]. Akt interacts with Smad3 and interferes 
with its phosphorylation and thus activation. TGF-, in turn, inhibits the formation of the Akt-
Smad3 complex. Hence, the ratio between Akt and Smad3 may determine the sensitivity or 
resistance against TGF- induced cell death [177, 178]. Comparison of the different HCC cell 
lines showed that basal Akt protein levels were rather stable while Smad3 levels varied, 
although without any correlation to the cytostatic TGF- response. However, Smad3 
expression and transcriptional activity was elevated by TGF- in cell death sensitive cells 
lines (Figure 3.13), which may result in an additional shift of the Akt/Smad3 towards 
functional Smad3. This is coherent with an observation that introduction of Akt into Hep3B 
cells inhibits TGF- induced apoptosis [176].          
4.1.3.3 PRAJA and ELF as regulators of Smad3 distribution 
ELF and PRAJA offer another explanation for different intensities of TGF- induced Smad3 
dependent cytostasis despite universal activation of Smad3. ELF interacts with Smad3 and 
escorts the active Smad3/Smad4 complex into the nucleus [182]. ELF is underrepresented in 
human HCCs. Furthermore, heterozygous ELF knockout mice spontaneously develop HCC 
[184]. E3 ligase PRAJA TGF- dependently interacts with ELF and initiates ubiquitination 
and degradation of ELF and Smad3. The grade of degradation and, thus, interference with 
Smad3 signaling is dependent on the amount of PRAJA [183], suggesting that the 
ELF/PRAJA ratio may define the fate of a cell upon TGF- stimulation. During liver 
regeneration, reduced ELF and increased PRAJA levels facilitate hepatocyte proliferation 
due to interference with growth limiting effects of TGF-. Consistently, ELF siRNA interferes 
with TGF- induced growth arrest and apoptosis in the hepatocyte cell line AML-12 [183, 
269]. ELF expression strongly varied between the different HCC cell lines analyzed (Figure 
3.15). In agreement with the discussed publications, five out of six liver cancer cell lines with 
the highest ELF/PRAJA ratio showed responsiveness to TGF- induced cell death or growth 
arrest. Interestingly, PRAJA is neither able to interact with Smad2 nor to induce degradation 
of Smad2 or Smad4 [182, 183]. The different roles of Smad2 and Smad3 during 
hepatocarcinogenesis are, until now, not fully understood. However, Smad3 seems to be the 
main mediator of TGF- induced cytostasis in hepatocytes and in the cell lines analyzed (see 
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chapter 4.1.2.3). A shift of the ELF/PRAJA balance towards PRAJA offers a mechanism to 
specifically attenuate or shut down (dependent on the ELF/PRAJA ratio) Smad3 signaling, 
while the Smad2 pathway remains functional. Both Smad2 and Smad3 have been linked to 
tumor progression in various cancers (chapter 4.1.2.3). Hence, further studies are needed to 
investigate the role of both R-Smads during liver cancer initiation and progression and if, 
e.g., an attenuation of Smad3 signaling (as observed in this study; Figure 3.11) instead of a 
complete disruption not only inhibits cytostatic effects of TGF-, but in parallel allows pro-
tumorigenic effects. 
In conclusion, TGF- develops complex cross-talking networks with various pathways 
in a cellular and context dependent manner. An acquisition of resistance against 
cytostatic effects of TGF- is a common feature of tumorigenesis. One possible 
mechanism to establish such resistance is a reduction of ELF levels, leading to 
attenuated Smad3 signaling. Another frequent observation is a shift from canonical, 
with often anti-tumorigenic functionalities, to non-canonical TGF- signaling (ERK, 
JNK), which usually exerts tumor-promoting tasks. Elevated Smad7 levels possibly 
contribute to this rearrangement of TGF- signaling. The final outcome of TGF- in 
HCC cell lines likely depends on the balance of the different pathways, which 
complicates interpretation of the results.  
4.1.4 Clustering of HCC cell lines based on cytostatic TGF- response 
As discussed above, TGF- may exert ambiguous functions during hepatocarcinogenesis. In 
HCC, a resistance against anti-tumorigenic effects of TGF- is frequently developed, while 
pro-tumorigenic functions are preserved. This results in a switch of TGF- from a tumor 
suppressor to a potential tumor promoter.  
This study extends a first characterization of early and late TGF-β signatures in HCC [270] 
and offers an in-depth analysis of nine HCC and one hepatoblastoma cell lines regarding 
basal and induced TGF- signaling and its impact on cell death and proliferation. The results 
are summarized in Figure 4.1 and suggest that the HCC cell lines can be in sorted into three 
groups.  
Group I: Responsiveness to TGF- induced cytostasis 
The first group consists of HepG2, PLC/PRF/5, Hep3B and HuH7 cells. All cell lines were 
sensitive to TGF- induced growth arrest and, except for HepG2, cell death. This phenotype 
was in general accompanied by relatively low endogenous TGF-1 and Smad7 expression 
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but high mRNA levels of its type II receptor (TRII). TGF- stimulation resulted in a) induction 
of TRI and Smad3 expression, b) by trend, prolonged Smad2 phosphorylation, c) enhanced 
Smad3/4 transcriptional activity and d) induction of TGF- target gene expression (Smad7, 
PAI-1, Bim). Interestingly, all cell lines of this group have been reported to belong to the 
group of HCC cell lines expressing early TGF--responsive genes (early TGF- signature), 
which correlated with a better prognosis in HCC patients [270]. 
Figure 4.1 Overview of endogenous expression levels and responses to TGF- stimulation in liver 
cancer cell lines. (TGF- dependent cytostasis, basal migratory capacity, induced TGF- signaling 
and inhibition of c-Myc expression) The darker the field, the stronger the reaction, or as in the case 
of proliferation, the earlier the observed TGF- mediated reaction emerged. Patterned fields 
highlight cell lines in which TGF- resulted in opposite effects compared to the other cell lines. 
(Basal TGF- signaling, survival signaling and ELF and PRAJA expression) The different gray 
scales represent different basal expression levels with increasing darkness for higher expression.
Group II: Resistance against cytostatic effects of TGF-  
The second group, consisting of HLE, HLF, FLC-4 and to some extent HuH6, exhibited 
contrary behavior. Except for a delayed inhibition of proliferation in HuH6 cells, TGF- was 
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unable to initiate any cytostatic responses. Furthermore, those cell lines expressed relatively 
high levels of TGF-1 and Smad7 but low levels of TRII when compared to group I. TGF-
treatment a) induced only short-term (transient) phosphorylation of Smad2, b) resulted in 
relatively low induction of Smad2 or Smad3 transcriptional activity and c) failed to intensively 
induce TRI expression and target genes such as Smad7, PAI-1 or Bim. Further basal ERK 
activation was increased when compared to group I and, except for HuH6, cell lines of this 
group had a high migratory capacity, which was accompanied by low E-cadherin and high 
basal PAI-1 expression and c-Jun activation. The special position of HuH6 in this group 
might be explained by the different origin (hepatoblastoma). Furthermore, HLE and HLF cells 
are assigned to the subgroup with a late TGF- signature, which correlated with higher basal 
invasion (in line with the migrative phenotype observed in this thesis) and poorer prognosis 
[270]. The cell line FLC-4 probably belongs to the same group as its behavior coincided with 
HLE and HLF cells. HuH6 was described as a cell line expressing early TGF--responsive 
genes [270], which could be another explanation for the outlying behavior of these cells.  
Group III: HCC-M and HCC-T cells 
Figure 4.1 further highlights that HCC-M and HCC-T cells exhibited outlying behavior, 
possessing characteristics of both groups described above. Like cell lines from group II, they 
had low levels of TRII and were completely resistant against TGF- induced cytostasis, 
whereas they expressed similar low levels of Smad7 and TGF-1 to TGF- sensitive cell 
lines (group I). Compared to sensitive cell lines from the first group, TGF-1 mediated 
induction of a) Smad3 or TRI expression, b) Smad3 or Smad2 transcriptional activity and c) 
TGF- target genes was strongly reduced, just as in group II.    
The impression, that the cell lines can be divided into three groups, two main groups and 
HCC-M and HCC-T cells, was confirmed by a hierarchical cluster analysis, which integrated 
all findings in regard to TGF- signaling, its cytostatic effects and regulation (Figure 4.2, 
kindly provided by Dr. Coulouarn, INSERM, UMR991, University of Rennes 1, Pontchaillou 
University Hospital, Rennes, France).  
HCC cell lines are an extensively used tool in liver cancer research. However, due to the 
diversity of different HCC cell lines, many contrary results on cellular processes and 
underlying mechanisms have been published so far. The results of this study will help to 
deepen the understanding of human hepatocarcinogenesis in regard of cytostatic TGF-
signaling and the frequently occurring shift from anti- to pro-tumorigenic effects of TGF-. It 
offers an itemized and comparative description of the role of TGF- signaling components 
during different cellular cytostatic TGF- responses. This facilitates the correct choice of cell 
lines to analyze specific aspects of HCC initiation and progression. 
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Figure 4.2 Hierarchical clustering analysis of liver cancer cell lines regarding TGF- signaling and 
cytostatic response. Cytostatic TGF- signaling related findings of this study (overview in Figure 
4.1) in one hepatoblastoma and 9 HCC cell lines were converted into an all-or-none fashion 
(black/white) to generate a matrix, which was then structured using a hierarchical clustering 
algorithm. Like in Figure 4.1, the different observations were assembled as followed (left side): (A) 
TGF- induced cytostasis (black: cell death >5%, growth inhibition >50%), (B) basal TGF-
signaling (black: rel. expression (2-∆∆Ct) >2.5 for all, but >4 for Smad3), (C) induced TGF-
signaling (black: rel. induction of expression (2-∆∆Ct)> 2, induction of CAGA and Smad7 promoter 
and expression > 2.8, induction of ARE reporter > 5, prolonged Smad phosphorylation), (D) survival 
signaling (black: increased or decreased (c-Myc) immunoblot signal), (E) basal ELF and PRAJA 
expression (black: rel. expression (2-∆∆Ct) > 6 (ELF) or > 1.2 (PRAJA)). Clustering analysis was 
performed by using Cluster3.0 software and the data were further visualized with TreeView1.6 
[270].  
HCC is one of the most common and deadliest cancers worldwide with, until now, limited 
treatment options. Hence, new therapeutic approaches are urgently needed. Targeting 
TGF- signaling is not only in constant discussion for treatment strategies against HCC, but 
also against other liver diseases such as fibrosis or cirrhosis. The described ambiguous 
functionality of TGF-, however, strongly complicates development of reliable therapies, 
which therefore requires an exact knowledge about the time point of the switch from anti- to 
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pro-tumorigenic TGF- features. The results of this PhD thesis highlight different possible 
mechanisms of resistance against cytostatic effects of TGF-, which might need different 
therapeutic targeting. Hence, the study offers for the first time the possibility of a systematic 
assortment of cell lines as investigation tools. Once pro-tumorigenic TGF- functionality is 
carefully deciphered as well, the cell lines can be sorted into groups of different TGF-
signature. Hopefully, this knowledge will then help to test new therapeutic strategies in the 
different cell lines in order to identify suitable, but also to exclude risky, approaches for the 
different groups.  
4.2  Smad7, a potential oncogene in liver cancer samples 
Aberrations of Smad2 and 4 are frequently found in different cancers (chapter 1.4.2). In 
contrast, basal Smad2, Smad3 (unlike induced) and Smad4 levels did not contribute to 
different cytostatic TGF- responsiveness in HCC cell lines, and alterations of the proteins 
play minor roles in human HCC (chapter 4.1.2.1). TRII reduction, on the other hand, was 
found in a subset of 25%-50% of HCCs [174, 181]. However, this occurred during loss of 
differentiation, suggesting that it is a rather late event during hepatocarcinogenesis. TRII is 
a key component for canonical, but also for non-canonical TGF- signaling. Hence, deletion 
of TRII possibly shuts down both, cytostatic and protumorigenic TGF- signaling. As TGF-
is frequently over-presented in HCC tissue [158, 159, 236, 237], it is likely that other 
strategies can be found in HCC, which include functional pro-tumorigenic but defective anti-
tumorigenic TGF- signaling.  
Smad7 is a potent inhibitor of TGF- signaling and is able to exert its functions at different 
levels of the TGF- signaling cascade (chapter 1.1.4.1). In parallel, it may interact with 
several other pathways (chapter 1.1.4.3). The results from the 10 different liver cancer cell 
lines suggest that Smad7 could be involved in developing a resistance against TGF-
mediated cytostatic effects (chapter 4.1.2.2). In line with that, Smad7 is involved in 
cancerogenesis of various tumors (chapter 1.4.3). Mostly, elevated Smad7 levels are linked 
to tumor progression and eventually correlate with increased tumor size, higher malignancy 
or poorer prognosis [208-216, 218-220] . Opposite findings were demonstrated for a few 
tumor species, in which Smad7 exerted protective effects in human patient samples or in 
murine cancer models [120, 206, 207, 217]. Analysis of a limited number of human HCC 
specimens suggests overexpression of Smad7 in HCC. Immunhistochemical analysis 
showed positive staining for Smad7 in 64% of HCCs and in only 36% of adjacent tissues 
[159]. In another study, Smad7 protein was present in 61% of advanced HBV related HCCs 
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(but not in dysplastic nodules) with no significant differences between tumor size, 
differentiation or vascular invasion. Interestingly, reduced TGF- receptor II mRNA levels 
predominantly occurred in HCCs with no detectable Smad7 levels [181], underlining the 
hypothesis of two alternative mechanisms to develop resistance against cytostatic TGF-
signaling. Independent of the endogenous Smad7 expression, TRII mRNA levels were 
reduced in all TGF- resistant HCC cell lines when compared to the sensitive ones (Figure 
3.4). However, in agreement with the results presented by Park et al [181], this reduction was 
lowest in HCC-M and HCC-T cells with very low Smad7 mRNA levels. To confirm the 
relevance of Smad7 during hepatocarcinogenesis, an expression analysis of 133 HCCs and 
matched non-tumorigenic liver tissues from Germany and China was performed. Smad7 was 
overexpressed in 59% of all HCCs (Figure 3.18), with a modestly higher frequency in 
samples collected in China when compared to those from Germany. Unlike Park et al., we 
found a significant (p=0.004) correlation between Smad7 and increasing tumor size in 
samples from China, whereas no differences were found in tissues from Germany. Chinese 
samples mainly derived from patients with HBV infection, just as in the cohort of Park et al., 
while tissues collected in Germany were mostly hepatitis negative. The discussed in vitro
data demonstrate that TGF- signaling outcome is not only dependent on the expression 
signature of its signaling components, but also on various cross-talks with other pathways. 
HBV and HCV related HCC, for example, is linked to activated ERK [180, 262, 266, 267], 
which is known to enhance Smad7 [109]. Hence, a comparative analysis of different TGF-
cross-talk pathways and Smad7 expression in HCC would be interesting. Furthermore, it 
should be evaluated if Smad7 and HBV exert synergistic effects on proliferation. Another in 
vitro finding was that highly motile HCC cell lines showed increased Smad7 expression. 
Unfortunately, clinicopathological information was too limited to perform a reliable correlation 
analysis between Smad7 expression and metastasis. Therefore, no further conclusions can 
be drawn if the in vitro data can be transferred to the in vivo situation. 
    
Taken together, the patient data and the results for the HCC cell lines suggest tumor 
promoting functions of Smad7 during hepatocarcinogenesis. Whether those are 
limited to inhibition of cytostatic effects of TGF- or whether Smad7 exerts additional 
pro-tumorigenic effects remains to be analyzed.  
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